Felix Feng, MD
Professor
Radiation Oncology
School of Medicine

Education & Training

Show all (3) Hide

• Residency Radiation Oncology University of Michigan 06/2010
• M.D. Medicine Washington University School of Medicine 06/2002
• B.S. Biological Sciences Stanford University 06/1998

Grants and Projects

Show all (4) Hide

• Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer, NIH, 2020-2025
• MELT: Modulation of PSMA Expression for Lutetium Therapy, NIH, 2019-2025
• Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies, NIH, 2018-2023
• DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications, NIH, 2018-2023

Publications (578)

Top publication keywords:
NomogramsProstatic Neoplasms, Castration-ResistantProstatectomyProstatic NeoplasmsRNA, Long NoncodingProstate-Specific AntigenSalvage TherapyBiomarkers, TumorGene Expression Regulation, NeoplasticReceptors, AndrogenAndrogen AntagonistsNeoplasm Recurrence, LocalPoly(ADP-ribose) Polymerase InhibitorsNeoplasm GradingProstate

• ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer.
  Cancer discovery 2024 Xu Y, Yang Y, Wang Z, Sjostrom M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J, Johnson NA, Li X, Li X, Metang LA, Mukherji A, Xu Q, Tirado CR, Wainwright G, Yu X, Barnes S, Hofstad M, Chen Y,…
• The Lancet Commission on prostate cancer: planning for the surge in cases.
  Lancet (London, England) 2024 James ND, Tannock I, N'Dow J, Feng F, Gillessen S, Ali SA, Trujillo B, Al-Lazikani B, Attard G, Bray F, Compérat E, Eeles R, Fatiregun O, Grist E, Halabi S, Haran Á, Herchenhorn D, Hofman M, Jalloh M,…
• CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.
  bioRxiv : the preprint server for biology 2024 Tien JC, Chang Y, Zhang Y, Chou J, Cheng Y, Wang X, Yang J, Mannan R, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, …
• Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.
  JAMA oncology 2024 Buyyounouski MK, Pugh SL, Chen RC, Mann MJ, Kudchadker RJ, Konski AA, Mian OY, Michalski JM, Vigneault E, Valicenti RK, Barkati M, Lawton CAF, Potters L, Monitto DC, Kittel JA, Schroeder TM, Hannan R,…
• Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.
  Cancer discovery 2024 Franceschini GM, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku SY, Sigouros M, Rothmann E, Alonso A, Benelli M, Nardella C, Auh J, Freeman D, Hanratty B, Adil M, Elemento O, Tagawa ST, Feng FY, Caffo O, …

Show all (573 more) Hide

• Canonical AREs are tumor suppressive regulatory elements in the prostate.
  bioRxiv : the preprint server for biology 2024 Augello MA, Chen X, Liu D, Lin K, Hakansson A, Sjöström M, Khani F, Deonarine LD, Liu Y, Travascio-Green J, Wu J, Loda M, Feng FY, Robinson BD, Davicioni E, Sboner A, Barbieri CE
• Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer.
  NPJ genomic medicine 2024 Saha D, Dang HX, Zhang M, Quigley DA, Feng FY, Maher CA
• Technical note: Errors introduced when using Dose Voxel Kernels for estimating absorbed dose from radiopharmaceutical therapies involving alpha emitters.
  Medical physics 2024 Tranel J, Palm S, Feng FY, St James S, Hope TA
• Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.
  European urology focus 2024 Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M, Tran PT, Souhami L, …
• External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial.
  European urology oncology 2024 Ross AE, Zhang J, Huang HC, Yamashita R, Keim-Malpass J, Simko JP, DeVries S, Morgan TM, Souhami L, Dobelbower MC, McGinnis LS, Jones CU, Dess RT, Zeitzer KL, Choi K, Hartford AC, Michalski JM, Raben …
• Large tandem duplications in cancer result from transcription and DNA replication collisions.
  medRxiv : the preprint server for health sciences 2024 Yang Y, Badura ML, O'Leary PC, Delavan HM, Robinson TM, Egusa EA, Zhong X, Swinderman JT, Li H, Zhang M, Kim M, Ashworth A, Feng FY, Chou J, Yang L
• Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
  British journal of cancer 2023 Zhao JL, Antonarakis ES, Cheng HH, George DJ, Aggarwal R, Riedel E, Sumiyoshi T, Schonhoft JD, Anderson A, Mao N, Haywood S, Decker B, Curley T, Abida W, Feng FY, Knudsen K, Carver B, Lacouture ME, …
• Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis.
  JAMA network open 2023 Mahal BA, Kwak L, Xie W, Eastham JA, James ND, Sandler HM, Feng FY, Brihoum M, Fizazi K, Sweeney C, Ravi P, D'Amico AV
• Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
  The Lancet. Oncology 2023 Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong…
• ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers.
  bioRxiv : the preprint server for biology 2023 Xu Y, Wang Z, Sjöström M, Deng S, Wang C, Johnson NA, Gonzalez J, Li X, Metang LA, Tirado CR, Mukherji A, Wainwright G, Yu X, Yang Y, Barnes S, Hofstad M, Zhu H, Hanker A, He HH, Chen Y, Wang Z, Raj G…
• Author Correction: Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer.
  Nature communications 2023 Nguyen T, Sridaran D, Chouhan S, Weimholt C, Wilson A, Luo J, Li T, Koomen J, Fang B, Putluri N, Sreekumar A, Feng FY, Mahajan K, Mahajan NP
• Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA.
  Cell 2023 Hosono Y, Niknafs YS, Prensner JR, Iyer MK, Dhanasekaran SM, Mehra R, Pitchiaya S, Tien J, Escara-Wilke J, Poliakov A, Chu SC, Saleh S, Sankar K, Su F, Guo S, Qiao Y, Freier SM, Bui HH, Cao X, Malik R…
• Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Roy S, Romero T, Michalski JM, Feng FY, Efstathiou JA, Lawton CAF, Bolla M, Maingon P, de Reijke T, Joseph D, Ong WL, Sydes MR, Dearnaley DP, Tree AC, Carrier N, Nabid A, Souhami L, Incrocci L, …
• Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer.
  NAR cancer 2023 Zivanovic A, Miller JT, Munro SA, Knutson TP, Li Y, Passow CN, Simonaitis P, Lynch M, Oseth L, Zhao SG, Feng FY, Wikström P, Corey E, Morrissey C, Henzler C, Raphael BJ, Dehm SM
• The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
  Cancer research 2023 Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, …
• Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.
  European urology oncology 2023 Sutera P, Shetty AC, Song Y, Hodges T, Hoang T, Rana Z, Pienta K, Feng F, Song DY, DeWeese T, Gillessen S, Sweeney C, James N, Attard G, Deek M, Tran PT
• Multi-institutional Development and External Validation of a Machine Learning Model for the Prediction of Distant Metastasis in Patients Treated by Salvage Radiotherapy for Biochemical Failure After Radical Prostatectomy.
  European urology focus 2023 Sabbagh A, Tilki D, Feng J, Huland H, Graefen M, Wiegel T, Böhmer D, Hong JC, Valdes G, Cowan JE, Cooperberg M, Feng FY, Mohammad T, Shelan M, D'Amico AV, Carroll PR, Mohamad O
• Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes.
  European urology oncology 2023 Chappidi MR, Sjöström M, Greenland NY, Cowan JE, Baskin AS, Shee K, Simko JP, Chan E, Stohr BA, Washington SL, Nguyen HG, Quigley DA, Davicioni E, Feng FY, Carroll PR, Cooperberg MR
• CT-based radiomics nomogram for the preoperative prediction of microsatellite instability and clinical outcomes in colorectal cancer: a multicentre study.
  Clinical radiology 2023 Li M, Xu G, Cui Y, Wang M, Wang H, Xu X, Duan S, Shi J, Feng F
• Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.
  European urology oncology 2023 Dahl DM, Karrison TG, Michaelson MD, Pham HT, Wu CL, Swanson GP, Shipley WU, Vuky J, Lee RJ, Zietman AL, Souhami L, Chang BK, Deming RL, Ellerton JA, Sandler HM, Rodgers JP, Feng FY, Efstathiou JA
• The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.
  European urology oncology 2023 Sood A, Kishan AU, Evans CP, Feng FY, Morgan TM, Murphy DG, Padhani AR, Pinto P, Van der Poel HG, Tilki D, Briganti A, Abdollah F
• Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology.
  Seminars in radiation oncology 2023 Sutera P, Skinner H, Witek M, Mishra M, Kwok Y, Davicioni E, Feng F, Song D, Nichols E, Tran PT, Bergom C
• Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer.
  NEJM evidence 2023 Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J…
• Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies.
  European urology 2023 Feng F, Miladinovic B, Zhang K, Dignam JJ, Wang D, Yu M, Sandler H
• Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.
  Annals of oncology : official journal of the European Society for Medical Oncology 2023 Helzer KT, Sharifi MN, Sperger JM, Shi Y, Annala M, Bootsma ML, Reese SR, Taylor A, Kaufmann KR, Krause HK, Schehr JL, Sethakorn N, Kosoff D, Kyriakopoulos C, Burkard ME, Rydzewski NR, Yu M, Harari PM…
• Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer.
  Nature communications 2023 Nguyen T, Sridaran D, Chouhan S, Weimholt C, Wilson A, Luo J, Li T, Koomen J, Fang B, Putluri N, Sreekumar A, Feng FY, Mahajan K, Mahajan NP
• Reply to V. Nardone et al.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Sjöström M, Fyles A, Liu FF, McCready D, Feng FY, Speers CW, Pierce LJ, Holmberg E, Fernö M, Malmström P, Karlsson P
• Integrative identification of non-coding regulatory regions driving metastatic prostate cancer.
  bioRxiv : the preprint server for biology 2023 Woo BJ, Moussavi-Baygi R, Karner H, Karimzadeh M, Garcia K, Joshi T, Yin K, Navickas A, Gilbert LA, Wang B, Asgharian H, Feng FY, Goodarzi H
• Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.
  European urology 2023 Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Jones CU, Horwitz EM, …
• Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
  European urology 2023 Sutera P, Song Y, Van der Eecken K, Shetty AC, English K, Hodges T, Chang J, Fonteyne V, Rana Z, Ren L, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Song DY, Pienta K, Feng FY, Joniau S, Lotan T…
• Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.
  Annals of oncology : official journal of the European Society for Medical Oncology 2023 Sutera PA, Shetty AC, Hakansson A, Van der Eecken K, Song Y, Liu Y, Chang J, Fonteyne V, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Rana Z, Hodges T, Hamid A, Roberts N, Song DY, Pienta K, …
• Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.
  International journal of radiation oncology, biology, physics 2023 Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, …
• Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Stenmark Tullberg A, Sjöström M, Niméus E, Killander F, Chang SL, Feng FY, Speers CW, Pierce LJ, Kovács A, Lundstedt D, Holmberg E, Karlsson P
• Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer.
  Research square 2023 Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J…
• DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations.
  Cancer research 2023 Gallon J, Rodriguez-Calero A, Benjak A, Akhoundova D, Maletti S, Amstutz U, Hewer E, Genitsch V, Fleischmann A, Rushing EJ, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya AO, Bubendorf L, Moch …
• Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.
  JCI insight 2023 Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V, Adil M, Bakbak H, Quigley DA, Schweizer MT, Hawley JE, Kollath L, True LD, Feng FY, Bander NH, …
• Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning.
  Nature communications 2023 de Jong AC, Danyi A, van Riet J, de Wit R, Sjöström M, Feng F, de Ridder J, Lolkema MP
• Radiomics model and clinical scale for the preoperative diagnosis of silent corticotroph adenomas.
  Journal of endocrinological investigation 2023 Wang H, Chang J, Zhang W, Fang Y, Li S, Fan Y, Jiang S, Yao Y, Deng K, Lu L, Bao X, Feng F, Wang R, Feng M
• Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Chopra S, Trepka K, Sakhamuri S, Carretero-González A, Zhu J, Egusa E, Zhou J, Leung K, Zhao N, Hooshdaran N, Feng FY, Wells JA, Chou J, Evans MJ
• Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer.
  NEJM evidence 2023 Gharzai LA, Jiang R, Jaworski EM, Morales Rivera K, Dess RT, Jackson WC, Hartman HE, Mehra R, Kishan AU, Solanki AA, Schaeffer EM, Feng FY, Zaorsky NG, Berlin A, Ponsky L, Shoag J, Sun Y, Schipper MJ,…
• Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era.
  Prostate cancer and prostatic diseases 2023 Ma TM, Feng FY, Rosenthal SA, Rettig MB, Raldow AC, Spratt DE, Xiang M, Kishan AU
• Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
  European journal of cancer (Oxford, England : 1990) 2023 Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, …
• Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography.
  European urology oncology 2023 Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, Ma TM, Davicioni E, Xiang M, Kishan AU
• Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer.
  European urology oncology 2023 Sabbagh A, Washington SL, Tilki D, Hong JC, Feng J, Valdes G, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Cowan JE, Cooperberg M, Feng FY, Roach M, Trock BJ, Partin AW, D'Amico AV, Carroll…
• Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Tilki D, Chen MH, Wu J, Huland H, Graefen M, Mohamad O, Cowan JE, Feng FY, Carroll PR, D'Amico AV
• Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.
  NPJ digital medicine 2023 Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M, Pisansky TM, Monson JM, Naz F,…
• Radiomics nomogram integrating intratumoural and peritumoural features to predict lymph node metastasis and prognosis in clinical stage IA non-small cell lung cancer: a two-centre study.
  Clinical radiology 2023 Chen QL, Li MM, Xue T, Peng H, Shi J, Li YY, Duan SF, Feng F
• Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.
  Research square 2023 Parry MA, Grist E, Mendes L, Dutey-Magni P, Sachdeva A, Brawley C, Murphy L, Proudfoot J, Lall S, Liu Y, Friedrich S, Ismail M, Hoyle A, Ali A, Haran A, Wingate A, Zakka L, Wetterskog D, Amos CL, …
• New staging systems in nonmetastatic prostate cancer.
  Clinical advances in hematology & oncology : H&O 2023 Feng F
• Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.
  European urology 2023 Mell LK, Pugh SL, Jones CU, Nelson TJ, Zakeri K, Rose BS, Zeitzer KL, Gore EM, Bahary JP, Souhami L, Michalski JM, Hartford AC, Mishra MV, Roach M, Parliament MB, Choi KN, Pisansky TM, Husain SM, …
• Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
  Cancer research 2023 Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, …
• Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Sjöström M, Fyles A, Liu FF, McCready D, Shi W, Rey-McIntyre K, Chang SL, Feng FY, Speers CW, Pierce LJ, Holmberg E, Fernö M, Malmström P, Karlsson P
• Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.
  International journal of radiation oncology, biology, physics 2022 Nguyen PL, Huang HR, Spratt DE, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko JP, Pollack A, Dicker AP, Roach M, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, …
• Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.
  International journal of radiation oncology, biology, physics 2022 Lukka HR, Deshmukh S, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, Feng FY, Pugh…
• Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126.
  Cancer 2022 McDonald AM, DeMora L, Yang ES, Hoyle JM, Lenzie A, Williams GR, Michalski JM, Yee D, Bahary JP, Den RB, Roach M, Dess R, Mishra MV, Valicenti RK, Lau HY, Marcrom SR, Souhami L, Mendez LC, Chen Y, …
• Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
  European urology 2022 Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, …
• IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis.
  Cancer research communications 2022 DiNatale A, Worrede A, Iqbal W, Marchioli M, Toth A, Sjöström M, Zhu X, Corey E, Feng FY, Zhou W, Fatatis A
• Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
  Urologic oncology 2022 Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ
• The CIC-ERF co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression.
  eLife 2022 Gupta N, Song H, Wu W, Ponce RK, Lin YK, Kim JW, Small EJ, Feng FY, Huang FW, Okimoto RA
• Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance.
  Nature communications 2022 Sridaran D, Chouhan S, Mahajan K, Renganathan A, Weimholt C, Bhagwat S, Reimers M, Kim EH, Thakur MK, Saeed MA, Pachynski RK, Seeliger MA, Miller WT, Feng FY, Mahajan NP
• Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, Miller S, Proudfoot JA, Deek MP, Phillips R, Lotan T, Paller CJ, Marshall CH, Markowski M, Dipasquale S, Denmeade S, Carducci M, Eisenberger M, …
• PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors.
  Molecular cancer therapeutics 2022 Thomas A, Fontaine SD, Diolaiti ME, Desai P, Kumar R, Takahashi N, Sciuto L, Nichols S, Ashworth A, Feng FY, Ashley GW, Nguyen M, Pommier Y, Santi DV
• Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2.
  Cancer research 2022 O'Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, Shenoy T, Kale N, Carnevale J, Stevenson E, Quigley DA, Chou J, Feng FY, Swaney DL, Krogan NJ, Kim M, Diolaiti ME, Ashworth A
• The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
  Cancer research 2022 Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, …
• Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy.
  JAMA network open 2022 Magliocco AM, Moughan J, Miyamoto DT, Simko J, Shipley WU, Gray PJ, Hagan MP, Parliament M, Tester WJ, Zietman AL, McCarthy S, Saeed-Vafa D, Xiong Y, Ayral T, Hartford AC, Patel A, Rosenthal SA, Chafe…
• The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors.
  Nature communications 2022 Chen S, Petricca J, Ye W, Guan J, Zeng Y, Cheng N, Gong L, Shen SY, Hua JT, Crumbaker M, Fraser M, Liu S, Bratman SV, van der Kwast T, Pugh T, Joshua AM, De Carvalho DD, Chi KN, Awadalla P, Ji G, Feng…
• Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation Therapy.
  Practical radiation oncology 2022 Quinn TJ, Chapman D, Parzen J, Wahl DR, McNamara A, Dess R, Chan J, Feng F, Jackson WC, Hamstra D
• Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Ma TM, Sun Y, Malone S, Roach M, Dearnaley D, Pisansky TM, Feng FY, Sandler HM, Efstathiou JA, Syndikus I, Hall EC, Tree AC, Sydes MR, Cruickshank C, Roy S, Bolla M, Maingon P, De Reijke T, Nabid A, …
• Molecular Genetics of Prostate Cancer and Role of Genomic Testing.
  Surgical pathology clinics 2022 Akhoundova D, Feng FY, Pritchard CC, Rubin MA
• Impact of radiopharmaceutical therapy (177Lu, 225Ac) microdistribution in a cancer-associated fibroblasts model.
  EJNMMI physics 2022 Tranel J, Palm S, Graves SA, Feng FY, Hope TA
• External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.
  International journal of radiation oncology, biology, physics 2022 Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY,…
• The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy - Authors' reply.
  Lancet (London, England) 2022 Pollack A, Karrison TG, Feng F, Sartor O, Sandler HM
• Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
  Nature communications 2022 Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, …
• Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.
  Cancer discovery 2022 Linder S, Hoogstraat M, Stelloo S, Eickhoff N, Schuurman K, de Barros H, Alkemade M, Bekers EM, Severson TM, Sanders J, Huang CF, Morova T, Altintas UB, Hoekman L, Kim Y, Baca SC, Sjöström M, Zaalberg…
• Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, …
• [Efficacy and safety of combination therapy with chemotherapy, programmed death-1 inhibitor and anlotinib in the treatment of advanced dedifferentiated liposarcoma].
  Zhonghua yi xue za zhi 2022 Guo X, Zhuang RY, Zhou YH, You CL, Zhang Y, Feng F, Shen ZM, Wang WS, Liu Y, Zhang HX, Tong WQ, Lu RK, Luo R
• Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).
  European urology 2022 Ma TM, Chu FI, Sandler H, Feng FY, Efstathiou JA, Jones CU, Roach M, Rosenthal SA, Pisansky T, Michalski JM, Bolla M, de Reijke TM, Maingon P, Neven A, Denham J, Steigler A, Joseph D, Nabid A, Souhami…
• Genomic biomarkers to guide precision radiotherapy in prostate cancer.
  The Prostate 2022 Sutera P, Deek MP, Van der Eecken K, Wyatt AW, Kishan AU, Molitoris JK, Ferris MJ, Siddiqui MM, Rana Z, Mishra MV, Kwok Y, Davicioni E, Spratt DE, Ost P, Feng FY, Tran PT
• [A cognitive and attitude survey of the implementation of enhanced recovery after surgery in gastrointestinal surgery in China].
  Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2022 Feng XY, Zhang P, Nie H, Ji G, Yang B, Feng F, Wang SQ, Ma YM, Jiang K, Zhao QC
• Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
  Nature 2022 Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME, SU2C/PCF …
• CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, …
• Prognostic predictors of non-small cell lung cancer treated with curative resection: the role of preoperative CT texture features, clinical features, and laboratory parameters.
  Clinical radiology 2022 Zhou L, Feng F, Yang Y, Zheng X, Yang Y
• Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Jackson WC, Tang M, Schipper MJ, Sandler HM, Zumsteg ZS, Efstathiou JA, Shipley WU, Seiferheld W, Lukka HR, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Hall WA, Dess RT, Lovett RD, Balogh AG, Feng…
• [Angiotensin-converting enzyme 2 particapates in ozone-induced lung inflammation and airway remodeling in mice].
  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2022 Wang Y, Zhang Y, Zhang L, Li M, Zhu P, Ji W, Liang R, Qiin L, Wu W, Feng F, Jin Y
• Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting.
  Science translational medicine 2022 Sawant M, Mahajan K, Renganathan A, Weimholt C, Luo J, Kukshal V, Jez JM, Jeon MS, Zhang B, Li T, Fang B, Luo Y, Lawrence NJ, Lawrence HR, Feng FY, Mahajan NP
• Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.
  NPJ digital medicine 2022 Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M, Pisansky TM, Monson JM, Naz F,…
• A study on serum pro-neurotensin (PNT), furin, and zinc alpha-2-glycoprotein (ZAG) levels in patients with acromegaly.
  Journal of endocrinological investigation 2022 Ke X, Duan L, Gong F, Zhang Y, Deng K, Yao Y, Wang L, Feng F, Xing B, Pan H, Zhu H
• The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521.
  International journal of radiation oncology, biology, physics 2022 Hall WA, Karrison TG, Rosenthal SA, Amin MB, Gomella LG, Purdy JA, Sartor AO, Michalski JM, Garzotto MG, Bergom C, Jani AB, Lawton CAF, Simko JP, Moore JK, Gore EM, Lee WR, Nguyen PL, Danielson BL, …
• Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415.
  JCO clinical cancer informatics 2022 Khairnar R, DeMora L, Sandler HM, Lee WR, Villalonga-Olives E, Mullins CD, Palumbo FB, Bruner DW, Shaya FT, Bentzen SM, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Albert M, Currey AD, …
• The Time to Evaluate the Impact of PET PSMAs on Management of Prostate Cancer Is Now.
  International journal of radiation oncology, biology, physics 2022 Mohamad O, Feng F
• Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome.
  JCI insight 2022 Qiu X, Brown LG, Conner JL, Nguyen HM, Boufaied N, Abou Alaiwi S, Seo JH, El Zarif T, Bell C, O'Connor E, Hanratty B, Pomerantz M, Freedman ML, Brown M, Haffner MC, Nelson PS, Feng FY, Labbé DP, Long …
• The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
  Lancet (London, England) 2022 Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, Wefel JS, Martin AG, Michalski JM, Angyalfi SJ, Lukka H, Faria SL, Rodrigues GB, Beauchemin MC, Lee RJ, Seaward SA, Allen AM, Monitto …
• Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.
  Clinical epigenetics 2022 Severson T, Qiu X, Alshalalfa M, Sjöström M, Quigley D, Bergman A, Long H, Feng F, Freedman ML, Zwart W, Pomerantz MM
• High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
  European urology 2022 Kishan AU, Wang X, Sun Y, Romero T, Michalski JM, Ma TM, Feng FY, Sandler HM, Bolla M, Maingon P, De Reijke T, Neven A, Steigler A, Denham JW, Joseph D, Nabid A, Carrier N, Souhami L, Sydes MR, …
• Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
  European urology 2022 Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou …
• Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].
  European urology 2022 Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, …
• A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.
  Molecular cancer 2022 Fletcher CE, Deng L, Orafidiya F, Yuan W, Lorentzen MPGS, Cyran OW, Varela-Carver A, Constantin TA, Leach DA, Dobbs FM, Figueiredo I, Gurel B, Parkes E, Bogdan D, Pereira RR, Zhao SG, Neeb A, Issa F, …
• Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial.
  Advances in radiation oncology 2022 Shee K, de la Calle CM, Chang AJ, Wong AC, Feng FY, Gottschalk AR, Carroll PR, Nguyen HG
• Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.
  JAMA oncology 2022 Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ…
• TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
  European urology oncology 2022 Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY
• What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
  European urology 2022 Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, …
• Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity.
  Molecular oncology 2022 Mazzu YZ, Liao Y, Nandakumar S, Sjöström M, Jehane LE, Ghale R, Govindarajan B, Gerke TA, Lee GM, Luo JH, Chinni SR, Mucci LA, Feng FY, Kantoff PW
• Selective vulnerabilities in the proteostasis network of castration-resistant prostate cancer.
  Cell chemical biology 2022 Shkedi A, Taylor IR, Echtenkamp F, Ramkumar P, Alshalalfa M, Rivera-Márquez GM, Moses MA, Shao H, Karnes RJ, Neckers L, Feng F, Kampmann M, Gestwicki JE
• Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1.
  Oncogene 2022 Melnyk JE, Steri V, Nguyen HG, Hwang YC, Gordan JD, Hann B, Feng FY, Shokat KM
• Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer.
  European urology 2022 Di Lalla V, Kucharczyk MJ, Wyatt AW, Feng FY, Probst S, Gravis G, So J, Saad F, Niazi T
• [Analysis of disease progression rate and related factors in amyotrophic lateral sclerosis patients at initial visit].
  Zhonghua yi xue za zhi 2022 Zhang JH, Wang HF, Yang F, He ZQ, Feng F, Li M, Bai JM, Wang HR, Huang XS
• [Prediction of platinum-based chemotherapy sensitivity for epithelial ovarian cancer by multi-sequence MRI-based radiomic nomogram].
  Zhonghua yi xue za zhi 2022 Mao MM, Li HM, Shi J, Qiu QS, Feng F
• Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.
  The Lancet. Oncology 2022 Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Souhami L, Dunne MT, Efstathiou JA, Sandler HM, Guerrero A, …
• Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.
  Prostate cancer and prostatic diseases 2022 Sutera P, Van Der Eecken K, Kishan AU, Hamid A, Grist E, Attard G, Lotan T, Mendes AA, Paller CJ, Carducci MA, Ross A, Wang H, Pienta K, Feng FY, Antonarakis ES, Ost P, Song DY, Greco S, Deville C, …
• Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states.
  Nature communications 2022 Song H, Weinstein HNW, Allegakoen P, Wadsworth MH, Xie J, Yang H, Castro EA, Lu KL, Stohr BA, Feng FY, Carroll PR, Wang B, Cooperberg MR, Shalek AK, Huang FW
• Prediction and verification of survival in patients with non-small-cell lung cancer based on an integrated radiomics nomogram.
  Clinical radiology 2021 Li R, Peng H, Xue T, Li J, Ge Y, Wang G, Feng F
• [Mid-term efficacy of sacral nerve stimulation for the treatment of chronic constipation].
  Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2021 He CX, Li SS, Du KL, Liu SQ, Zhang B, Feng F, Zheng JY
• The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
  Nature communications 2021 Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, …
• An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
  International journal of radiation oncology, biology, physics 2021 Roy S, Zaorsky NG, Bagshaw HP, Berlin A, Tree A, Turner S, Koontz B, Nguyen P, Chen R, Dess RT, Jackson WC, Kishan AU, Stish B, Nagar H, Posadas E, Tran PT, Solanki A, Shore ND, Guo G, Ponsky L, Shoag…
• Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
  European urology 2021 Saad F, Small EJ, Feng FY, Graff JN, Olmos D, Hadaschik BA, Oudard S, Londhe A, Bhaumik A, Lopez-Gitlitz A, Thomas S, Mundle SD, Chowdhury S, Smith MR
• Reply to M. K. Bos et al.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Sperger JM, Feng FY, Armstrong AJ, Zhao SG, Lang JM
• Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.
  JAMA network open 2021 Ma TM, Romero T, Nickols NG, Rettig MB, Garraway IP, Roach M, Michalski JM, Pisansky TM, Lee WR, Jones CU, Rosenthal SA, Wang C, Hartman H, Nguyen PL, Feng FY, Boutros PC, Saigal C, Chamie K, Jackson …
• Loss of Long Noncoding RNA NXTAR in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance.
  Cancer research 2021 Ghildiyal R, Sawant M, Renganathan A, Mahajan K, Kim EH, Luo J, Dang HX, Maher CA, Feng FY, Mahajan NP
• Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.
  JAMA oncology 2021 Aggarwal R, Rydzewski NR, Zhang L, Foye A, Kim W, Helzer KT, Bakhtiar H, Chang SL, Perry MD, Gleave M, Reiter RE, Huang J, Evans CP, Alumkal JJ, Lang JM, Yu M, Quigley DA, Sjöström M, Small EJ, Feng …
• Biological data annotation via a human-augmenting AI-based labeling system.
  NPJ digital medicine 2021 van der Wal D, Jhun I, Laklouk I, Nirschl J, Richer L, Rojansky R, Theparee T, Wheeler J, Sander J, Feng F, Mohamad O, Savarese S, Socher R, Esteva A
• [Methylation detection of phosphatase and tensin homolog deleted on chromosome ten gene promoter in hepatocellular carcinoma samples by next-generation sequencing].
  Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 2021 Jing XK, Jiang QY, Li CS, Zhang NR, Chai YT, Feng F, Li BA, Li YK
• Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2021 Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, Hofman M, Koontz BF, Lin DW, Morris MJ, Rowe SP, Royce TJ, Salami S, Savir-Baruch B, Srinivas S, Hope TA
• [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
  Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2021 Zhang P, Zhang J, Zhang B, Yang WC, Hu JB, Sun XF, Zhai G, Qian HR, Li Y, Xu H, Feng F, Wu XY, Liu HL, Liu HJ, Qiu HB, Wu XJ, Zhou YB, Shen KT, Kou YW, Fu Y, Jie ZG, Zou XM, Cao H, Gao ZD, Tao KX
• Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures.
  NPJ genomic medicine 2021 Rydzewski NR, Peterson E, Lang JM, Yu M, Laura Chang S, Sjöström M, Bakhtiar H, Song G, Helzer KT, Bootsma ML, Chen WS, Shrestha RM, Zhang M, Quigley DA, Aggarwal R, Small EJ, Wahl DR, Feng FY, Zhao …
• An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.
  Nature cell biology 2021 Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, Karaoglanoglu F, Omur ME, Kim S, Kobelev M, Kumar S, Sivak O, Bostock C, Bishop J, Hoogstraat M, Talal A, Stelloo S, van der Poel H, …
• Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.
  International journal of radiation oncology, biology, physics 2021 Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M, Yee D, …
• Model Selection for the Preclinical Development of New Drug-Radiotherapy Combinations.
  Clinical oncology (Royal College of Radiologists (Great Britain)) 2021 Singh J, Hatcher S, Ku AA, Ding Z, Feng FY, Sharma RA, Pfister SX
• Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE).
  Cancer genetics 2021 Swami N, Hwang WL, Guo JA, Hoffman H, Abramowitz MC, Elbakouny Z, Beltran H, Chipidza F, Choueiri T, Pra AD, Huang F, Kaochar S, Kantoff P, Kim DW, Kishan AU, Kobetz E, Marinac C, Mucci LA, Muralidhar…
• An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.
  Nature communications 2021 Das R, Sjöström M, Shrestha R, Yogodzinski C, Egusa EA, Chesner LN, Chen WS, Chou J, Dang DK, Swinderman JT, Ge A, Hua JT, Kabir S, Quigley DA, Small EJ, Ashworth A, Feng FY, Gilbert LA
• Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative.
  Prostate cancer and prostatic diseases 2021 Vince RA, Jiang R, Qi J, Tosoian JJ, Takele R, Feng FY, Linsell S, Johnson A, Shetty S, Hurley P, Miller DC, George A, Ghani K, Sun F, Seymore M, Dess RT, Jackson WC, Schipper M, Spratt DE, Morgan TM
• Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
  JAMA oncology 2021 Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, Small EJ
• Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Sperger JM, Emamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, Kwak L, Gilsdorf CS, Wolfe SK, Wei XX, Silver R, Zhang Z, Morris MJ, Bubley G, Feng FY, Scher HI, Rathkopf D, Dehm SM, Choueiri TK, …
• Treating Localized High-Risk Prostate Cancer: Do All Roads Lead to Rome?
  International journal of radiation oncology, biology, physics 2021 Mohamad O, Feng F
• BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman JA, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, …
• Constraints on Cosmic Strings Using Data from the Third Advanced LIGO-Virgo Observing Run.
  Physical review letters 2021 Abbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams A, Adams C, Adhikari RX, Adya VB, Affeldt C, Agarwal D, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Akutsu T, …
• The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics.
  Molecular cancer research : MCR 2021 Siefert JC, Cioni B, Muraro MJ, Alshalalfa M, Vivié J, van der Poel HG, Schoots IG, Bekers E, Feng FY, Wessels LFA, Zwart W, Bergman AM
• Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Hamid AA, Huang HC, Wang V, Chen YH, Feng F, Den R, Attard G, Van Allen EM, Tran PT, Spratt DE, Dittamore R, Davicioni E, Liu G, DiPaola R, Carducci MA, Sweeney CJ
• Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Smith MR, Thomas S, Gormley M, Chowdhury S, Olmos D, Oudard S, Feng FY, Rajpurohit Y, Urtishak K, Ricci DS, Rooney B, Lopez-Gitlitz A, Yu M, Wyatt AW, Li M, Attard G, Small EJ
• Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J
• A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?
  European journal of nuclear medicine and molecular imaging 2021 Salavati A, Gencturk M, Koksel Y, Schik AN, Carroll PR, Feng FY, Rowe SP, Lawhn-Heath C, Hope TA, Froelich JW
• Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Tilki D, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Mohamad O, Cowan JE, Feng FY, Carroll PR, Trock BJ, Partin AW, D'Amico AV
• Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences.
  Communications biology 2021 Rayford W, Beksac AT, Alger J, Alshalalfa M, Ahmed M, Khan I, Falagario UG, Liu Y, Davicioni E, Spratt DE, Schaeffer EM, Feng FY, Mahal B, Nguyen PL, Den RB, Greenberger MD, Bradley R, Watson JM, …
• [Successful surgical resection of primary cardiac angiosarcoma: a case report].
  Zhonghua xin xue guan bing za zhi 2021 Qu YL, Huang C, Zhu XH, Huang GC, Ma GF, Wang Y, Feng F, Xu J
• Functional mapping of androgen receptor enhancer activity.
  Genome biology 2021 Huang CF, Lingadahalli S, Morova T, Ozturan D, Hu E, Yu IPL, Linder S, Hoogstraat M, Stelloo S, Sar F, van der Poel H, Altintas UB, Saffarzadeh M, Le Bihan S, McConeghy B, Gokbayrak B, Feng FY, Gleave…
• Long noncoding RNAs in cancer metastasis.
  Nature reviews. Cancer 2021 Liu SJ, Dang HX, Lim DA, Feng FY, Maher CA
• Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.
  JCO precision oncology 2021 Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Kageyama R, Wells DK, Chan JM, Friedlander T, Aggarwal R, Paris PL, Feng F, Carroll PR, Witte JS
• Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.
  PloS one 2021 Khairnar R, Pugh SL, Sandler HM, Lee WR, Villalonga Olives E, Mullins CD, Palumbo FB, Bruner DW, Shaya FT, Bentzen SM, Shah AB, Malone SC, Michalski JM, Dayes IS, Seaward SA, Albert M, Currey AD, …
• Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
  European urology 2021 Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, …
• Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
  JAMA oncology 2021 Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, …
• Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.
  European urology 2021 Kumaraswamy A, Welker Leng KR, Westbrook TC, Yates JA, Zhao SG, Evans CP, Feng FY, Morgan TM, Alumkal JJ
• CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer.
  Nature communications 2021 Ahmed M, Soares F, Xia JH, Yang Y, Li J, Guo H, Su P, Tian Y, Lee HJ, Wang M, Akhtar N, Houlahan KE, Bosch A, Zhou S, Mazrooei P, Hua JT, Chen S, Petricca J, Zeng Y, Davies A, Fraser M, Quigley DA, …
• Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
  Cancer 2021 Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS
• Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.
  Scientific reports 2021 Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS
• Circ_0061140 promotes metastasis of bladder cancer through adsorbing microRNA-1236.
  European review for medical and pharmacological sciences 2021 Feng F, Chen AP, Wang XL, Wu GL
• Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.
  The Lancet. Oncology 2021 Gharzai LA, Jiang R, Wallington D, Jones G, Birer S, Jairath N, Jaworski EM, McFarlane MR, Mahal BA, Nguyen PL, Sandler H, Morgan TM, Reichert ZR, Alumkal JJ, Mehra R, Kishan AU, Fizazi K, Halabi S, …
• Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
  European urology oncology 2021 Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, …
• Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow.
  Physics in medicine and biology 2021 Tranel J, Feng FY, James SS, Hope TA
• The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair.
  Nature communications 2021 Shafi AA, McNair CM, McCann JJ, Alshalalfa M, Shostak A, Severson TM, Zhu Y, Bergman A, Gordon N, Mandigo AC, Chand SN, Gallagher P, Dylgjeri E, Laufer TS, Vasilevskaya IA, Schiewer MJ, Brunner M, …
• The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
  European urology 2021 Deek MP, Van der Eecken K, Phillips R, Parikh NR, Isaacsson Velho P, Lotan TL, Kishan AU, Maurer T, GAP6 Consortium, Boutros PC, Hovens C, Abramowtiz M, Pollack A, Desai N, Stish B, Feng FY, …
• Preserving Well-being in Patients With Advanced and Late Prostate Cancer.
  Urology 2020 Handley NR, Feng FY, Guise TA, D'Andrea D, Kelly WK, Gomella LG
• Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary.
  Urology 2020 Hofmann MR, Hussain M, Dehm SM, Beltran H, Wyatt AW, Halabi S, Sweeney C, Scher HI, Ryan CJ, Feng FY, Attard G, Klein E, Miyahira AK, Soule HR, Sharifi N
• Early salvage versus adjuvant therapy for treatment of prostate cancer following prostatectomy.
  BMJ evidence-based medicine 2020 Garriga M, Feng FY, Lee WR, Hong JC
• Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo…
• Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer.
  European urology 2020 Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, …
• A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer.
  European urology 2020 Jairath NK, Dal Pra A, Vince R, Dess RT, Jackson WC, Tosoian JJ, McBride SM, Zhao SG, Berlin A, Mahal BA, Kishan AU, Den RB, Freedland SJ, Salami SS, Kaffenberger SD, Pollack A, Tran P, Mehra R, …
• Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee …
• Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.
  JAMA oncology 2020 Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, Davis BJ, Horwitz EM, Terris MK, Amling CL, Aronson WJ, Kane CJ, Jackson WC, Hearn JWD, Deville C, DeWeese TL, Greco S, McNutt TR…
• Accelerating precision medicine in metastatic prostate cancer.
  Nature cancer 2020 Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, Rettig M, Schultz N, Smith M, Solit D, Sternberg C, Van …
• Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes.
  European urology open science 2020 Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, Venkadakrishnan VB, Senapati D, Kumari S, Liu D, Sboner A, Barbieri CE, Feng F, Billaud JN, Davicioni E, Liu S, Heemers HV
• Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Stenmark Tullberg A, Puttonen HAJ, Sjöström M, Holmberg E, Chang SL, Feng FY, Speers C, Pierce LJ, Lundstedt D, Killander F, Niméus E, Kovács A, Karlsson P
• Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.
  Nature communications 2020 Cyrta J, Augspach A, De Filippo MR, Prandi D, Thienger P, Benelli M, Cooley V, Bareja R, Wilkes D, Chae SS, Cavaliere P, Dephoure N, Uldry AC, Lagache SB, Roma L, Cohen S, Jaquet M, Brandt LP, …
• Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate.
  JCO precision oncology 2020 Hall WA, Fishbane N, Liu Y, Xu MJ, Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Schaeffer EM, Karnes RJ, Carroll PR, Cooperberg MR, Bismar TA, Kim HL, Klein EA, Davis JW, Ross AE, …
• A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance.
  Nature cancer 2020 Arriaga JM, Panja S, Alshalalfa M, Zhao J, Zou M, Giacobbe A, Madubata CJ, Kim JY, Rodriguez A, Coleman I, Virk RK, Hibshoosh H, Ertunc O, Ozbek B, Fountain J, Jeffrey Karnes R, Luo J, Antonarakis ES,…
• Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.
  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2020 Levin-Epstein RG, Jiang NY, Wang X, Upadhyaya SK, Collins SP, Suy S, Aghdam N, Mantz C, Katz AJ, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas N, Bagshaw H, Buyyounouski MK, Cao M, Agazaryan N,…
• Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA.
  Living reviews in relativity 2020 Abbott BP, Abbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams C, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Akutsu T, Allen G, Allocca A, Aloy…
• SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression.
  Scientific reports 2020 Eteleeb AM, Quigley DA, Zhao SG, Pham D, Yang R, Dehm SM, Luo J, Feng FY, Dang HX, Maher CA
• Autoantibody Landscape in Patients with Advanced Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M…
• GW190521: A Binary Black Hole Merger with a Total Mass of 150  M_{⊙}.
  Physical review letters 2020 Abbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams C, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aich A, Aiello L, Ain A, Ajith P, Akcay S, Allen G, …
• NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer.
  International journal of radiation oncology, biology, physics 2020 Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, …
• The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
  Bioorganic & medicinal chemistry 2020 Melnyk JE, Steri V, Nguyen HG, Hann B, Feng FY, Shokat KM
• False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.
  European journal of nuclear medicine and molecular imaging 2020 Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU, PSMA PET Reader Group, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin…
• Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer.
  Clinical genitourinary cancer 2020 Chipidza FE, Alshalalfa M, Mahal BA, Karnes RJ, Liu Y, Davicioni E, Martin NE, Mouw KW, Feng FY, Nguyen PL, Muralidhar V
• Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making.
  Urology 2020 Lamba N, Butler S, Mahal BA, Trinh QD, Rose B, King M, Orio P, Mouw KW, Martin N, Leeman JE, Feng FY, Nguyen PL, Muralidhar V
• Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, …
• A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, Lakhotia S, Feng FY, Small EJ, Abida W, Alumkal JJ
• The DNA methylation landscape of advanced prostate cancer.
  Nature genetics 2020 Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, …
• Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.
  Urologic oncology 2020 Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small …
• Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes.
  Journal of clinical medicine 2020 Jairath NK, Farha MW, Srinivasan S, Jairath R, Green MD, Dess RT, Jackson WC, Weiner AB, Schaeffer EM, Zhao SG, Feng FY, El Naqa I, Spratt DE
• [Clinical analysis of mediastinal lymph node dissection through sternotomy approach in the treatment of papillary thyroid carcinoma with mediastinal lymph node metastasis].
  Zhonghua yi xue za zhi 2020 Shao K, Gao SG, Xue Q, Gao YS, Li J, Wang YG, Li ZS, Lei WD, Wang B, Feng FY, Lyu F, Chen XJ, Xu ZG, Liu WS, Liu SY, Wang XL, Li ZJ, Liu J, He J
• Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.
  International journal of radiation oncology, biology, physics 2020 Tabrizi S, Alshalalfa M, Mahal BA, Davicioni E, Liu Y, Mouw KW, Feng F, Nguyen PL, Muralidhar V
• Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
  International journal of radiation oncology, biology, physics 2020 Parikh NR, Chang EM, Nickols NG, Rettig MB, Raldow AC, Steinberg ML, Koontz BF, Vapiwala N, Deville C, Feng FY, Spratt DE, Reiter RE, Phillips R, Ost P, Tran PT, Kishan AU
• Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons …
• Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer.
  European urology 2020 Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng…
• Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
  Proceedings of the National Academy of Sciences of the United States of America 2020 Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, …
• A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences.
  International journal of radiation oncology, biology, physics 2020 Speers C, Chang SL, Pesch A, Ritter C, Olsen E, Chandler B, Moubadder L, Liu M, Cameron M, Michmerhuizen A, Wilder-Romans K, Zhao SG, Nyati S, Bartelink H, Feng FY, Pierce LJ
• Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
  Cancer research 2020 Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, Rettig MB, Yu J
• Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, Reichert ZR, Kishan AU, Mahal BA, Zumsteg ZS, Efstathiou JA, Kaffenberger S, Morgan TM, Mehra R, Showalter TN, Krauss DA, Nguyen PL, …
• Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.
  JAMA oncology 2020 Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, …
• Circ_0061140 promotes metastasis of bladder cancer through adsorbing microRNA-1236.
  European review for medical and pharmacological sciences 2020 Feng F, Chen AP, Wang XL, Wu GL
• Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2020 McKay RR, Feng FY, Wang AY, Wallis CJD, Moses KA
• Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
  Prostate cancer and prostatic diseases 2020 Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, Feng F, Stuart JM, Small EJ
• Intermediate-risk Prostate Cancer: Stratification and Management.
  European urology oncology 2020 Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, Klotz L, Montironi R, Nguyen PL, D'Amico AV
• Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier.
  Prostate cancer and prostatic diseases 2020 Tosoian JJ, Birer SR, Jeffrey Karnes R, Zhang J, Davicioni E, Klein EE, Freedland SJ, Weinmann S, Trock BJ, Dess RT, Zhao SG, Jackson WC, Yamoah K, Dal Pra A, Mahal BA, Morgan TM, Mehra R, …
• Neddylation inactivation represses androgen receptor transcription and inhibits growth, survival and invasion of prostate cancer cells.
  Neoplasia (New York, N.Y.) 2020 Zhou X, Han S, Wilder-Romans K, Sun GY, Zhu H, Liu X, Tan M, Wang G, Feng FY, Sun Y
• Rapamycin (sirolimus) in treatment of recurrent intravenous leiomyomatosis: a case report.
  BJOG : an international journal of obstetrics and gynaecology 2020 Zhang G, Feng F, Wang W, Zhu L
• Molecular chemisorption of N2 on IrO2(110).
  The Journal of chemical physics 2020 Martin R, Kim M, Lee CJ, Shariff MS, Feng F, Meyer RJ, Asthagiri A, Weaver JF
• Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, Voog EG, Bryce AH, McDermott R, Ricci F, Rowe J, Zhang J, Piulats JM, Fizazi K, Merseburger AS, Higano CS, Krieger LE, Ryan CJ, …
• Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
  Cancer discovery 2020 Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A
• Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
  Frontiers in endocrinology 2020 Michmerhuizen AR, Chandler B, Olsen E, Wilder-Romans K, Moubadder L, Liu M, Pesch AM, Zhang A, Ritter C, Ward ST, Santola A, Nyati S, Rae JM, Hayes D, Feng FY, Spratt D, Wahl D, Eisner J, Pierce LJ, …
• Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
  European urology 2020 Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, …
• Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Li Y, Yang R, Henzler CM, Ho Y, Passow C, Auch B, Carreira S, Nava Rodrigues D, Bertan C, Hwang TH, Quigley DA, Dang HX, Morrissey C, Fraser M, Plymate SR, Maher CA, Feng FY, de Bono JS, Dehm SM
• [Awareness, treatment and control of hypertension in 640 000 adults in eastern China].
  Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 2020 Yan XF, Yang JW, Bai XK, Wang HR, Feng F, Hou LL, Sun Y, Wang WJ, Li X
• Genomic and clinical characterization of stromal infiltration markers in prostate cancer.
  Cancer 2020 Mahal BA, Alshalalfa M, Zhao SG, Beltran H, Chen WS, Chipidza F, Davicioni E, Karnes RJ, Ku SY, Lotan TL, Muralidhar V, Rebbeck TR, Schaeffer EM, Spratt DE, Feng FY, Nguyen PL
• Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
  Cancer 2019 Butler SS, Muralidhar V, Zhao SG, Sanford NN, Franco I, Fullerton ZH, Chavez J, D'Amico AV, Feng FY, Rebbeck TR, Nguyen PL, Mahal BA
• Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.
  European urology 2019 Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed …
• Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
  European urology 2019 Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J
• Middle Cerebral Artery Plaque Hyperintensity on T2-Weighted Vessel Wall Imaging Is Associated with Ischemic Stroke.
  AJNR. American journal of neuroradiology 2019 Yu YN, Liu MW, Villablanca JP, Li ML, Xu YY, Gao S, Feng F, Liebeskind DS, Scalzo F, Xu WH
• Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Sjöström M, Chang SL, Fishbane N, Davicioni E, Zhao SG, Hartman L, Holmberg E, Feng FY, Speers CW, Pierce LJ, Malmström P, Fernö M, Karlsson P
• Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sjöström M, Chang SL, Fishbane N, Davicioni E, Hartman L, Holmberg E, Feng FY, Speers CW, Pierce LJ, Malmström P, Fernö M, Karlsson P
• Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902.
  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2019 Hamstra DA, Pugh SL, Lepor H, Rosenthal SA, Pienta KJ, Gomella L, Peters C, D'Souza DP, Zeitzer KL, Jones CU, Hall WA, Horwitz E, Pisansky TM, Souhami L, Hartford AC, Dominello M, Feng F, Sandler HM
• Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen …
• Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
  Neuro-oncology 2019 Zhao SG, Yu M, Spratt DE, Chang SL, Feng FY, Kim MM, Speers CW, Carlson BL, Mladek AC, Lawrence TS, Sarkaria JN, Wahl DR
• [The correlation of functional connectivity and structural connectivity between hippocampus and thalamus in Alzheimer's disease and amnestic mild cognitive impairment].
  Zhonghua nei ke za zhi 2019 Feng F, Zhou B, Wang L, Yao HX, Guo YE, An NY, Wang LN, Zhang X
• Author Correction: Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms.
  Nature communications 2019 Emami NC, Kachuri L, Meyers TJ, Das R, Hoffman JD, Hoffmann TJ, Hu D, Shan J, Feng FY, Ziv E, Van Den Eeden SK, Witte JS
• Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance.
  Prostate cancer and prostatic diseases 2019 Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR
• Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms.
  Nature communications 2019 Emami NC, Kachuri L, Meyers TJ, Das R, Hoffman JD, Hoffmann TJ, Hu D, Shan J, Feng FY, Ziv E, Van Den Eeden SK, Witte JS
• DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley …
• Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer.
  International journal of radiation oncology, biology, physics 2019 Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, Spratt DE, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL
• Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Dylgjeri E, McNair C, Goodwin JF, Raymon HK, McCue PA, Shafi AA, Leiby BE, de Leeuw R, Kothari V, McCann JJ, Mandigo AC, Chand SN, Schiewer MJ, Brand LJ, Vasilevskaya I, Gordon N, Laufer TS, Gomella …
• Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.
  JAMA oncology 2019 Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, …
• Author Reply.
  Urology 2019 Boreta L, Gadzinski AJ, Hope TA, Feng FY
• Reply to J.B. Aragon-Ching.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Rosenthal SA, Hu C, Sartor O, Feng FY, Sandler HM
• Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.
  Cancer 2019 Mahal AR, Butler S, Franco I, Muralidhar V, Larios D, Pike LRG, Zhao SG, Sanford NN, Dess RT, Feng FY, D'Amico AV, Spratt DE, Yu JB, Nguyen PL, Rebbeck TR, Mahal BA
• Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
  Nature 2019 Parolia A, Cieslik M, Chu SC, Xiao L, Ouchi T, Zhang Y, Wang X, Vats P, Cao X, Pitchiaya S, Su F, Wang R, Feng FY, Wu YM, Lonigro RJ, Robinson DR, Chinnaiyan AM
• Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.
  European urology oncology 2019 Alshalalfa M, Nguyen PL, Beltran H, Chen WS, Davicioni E, Zhao SG, Rebbeck TR, Schaeffer EM, Lotan TL, Feng FY, Mahal BA
• Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
  JAMA oncology 2019 Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R,…
• Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer.
  JCO precision oncology 2019 Salami SS, Singhal U, Spratt DE, Palapattu GS, Hollenbeck BK, Schonhoft JD, Graf R, Louw J, Jendrisak A, Dugan L, Wang Y, Tomlins SA, Dittamore R, Feng FY, Morgan TM
• Active Surveillance for Low-Risk Prostate Cancer in Black Patients.
  The New England journal of medicine 2019 Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA
• The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.
  European urology 2019 Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF
• Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers.
  Molecular cancer research : MCR 2019 Goswami MT, VanDenBerg KR, Han S, Wang LL, Singh B, Weiss T, Barlow M, Kamberov S, Wilder-Romans K, Rhodes DR, Feng FY, Tomlins SA
• The current state of randomized clinical trial evidence for prostate brachytherapy.
  Urologic oncology 2019 Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE
• Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer.
  AJR. American journal of roentgenology 2019 Lawhn-Heath C, Flavell RR, Behr SC, Yohannan T, Greene KL, Feng F, Carroll PR, Hope TA
• Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY
• [Analysis of spatial-temporal distribution of pesticide poisoning in Quzhou, 2013-2017].
  Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases 2019 Zheng XW, Nie Z, Zheng Z, Liu SF, Feng F
• A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
  Theranostics 2019 Jan YJ, Yoon J, Chen JF, Teng PC, Yao N, Cheng S, Lozano A, Chu GCY, Chung H, Lu YT, Chen PJ, Wang JJ, Lee YT, Kim M, Zhu Y, Knudsen BS, Feng FY, Garraway IP, Gao AC, Chung LWK, Freeman MR, You S, …
• Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.
  International journal of radiation oncology, biology, physics 2019 Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N,…
• Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
  Cancer research 2019 Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, Rettig MB, Yu J
• Lethal clues to cancer-cell vulnerability.
  Nature 2019 Feng FY, Gilbert LA
• Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
  European urology 2019 Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, …
• Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy.
  Urology 2019 Boreta L, Gadzinski AJ, Wu SY, Xu M, Greene K, Quanstrom K, Nguyen HG, Carroll PR, Hope TA, Feng FY
• Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.
  Molecular cancer research : MCR 2019 Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ
• A C-type lectin with a single carbohydrate-recognition domain involved in the innate immune response of Tribolium castaneum.
  Insect molecular biology 2019 Bi J, Feng F, Li J, Mao J, Ning M, Song X, Xie J, Tang J, Li B
• A Tumor-Agnostic NTRK (TRK) Inhibitor.
  Cell 2019 Huang FW, Feng FY
• Comparison of Population-Based Observational Studies With Randomized Trials in Oncology.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Soni PD, Hartman HE, Dess RT, Abugharib A, Allen SG, Feng FY, Zietman AL, Jagsi R, Schipper MJ, Spratt DE
• Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset.
  European urology 2019 Knudsen KE, Feng FY
• Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, …
• [The correlation of ganglion cell layer thickness with visual field defect in non-functional pituitary adenoma with chiasm compression].
  [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 2019 Zhang X, Ma J, Wang YH, Gan LY, Li L, Wang XQ, Li DH, Xing B, Feng M, Zhu HJ, Lu L, Feng F, You H, Zhang ZH, Zhong Y
• The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program.
  Molecular oncology 2019 Parolia A, Venalainen E, Xue H, Mather R, Lin D, Wu R, Pucci P, Rogalski J, Evans JR, Feng F, Collins CC, Wang Y, Crea F
• AUTHOR REPLY.
  Urology 2019 Wu SY, Feng FY, Hope TA
• Altered exosomal miR-181d and miR-30a related to the pathogenesis of CVB3 induced myocarditis by targeting SOCS3.
  European review for medical and pharmacological sciences 2019 Fan KL, Li MF, Cui F, Feng F, Kong L, Zhang FH, Hao H, Yin MX, Liu Y
• The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
  Journal of the National Cancer Institute 2019 Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, …
• MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
  Prostate cancer and prostatic diseases 2019 Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, …
• "Lincing" the Y Chromosome to Prostate Cancer: TTTY15 Takes Center Stage.
  European urology 2019 Prensner JR, Feng FY
• Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer.
  European urology focus 2019 Vicier C, Feng FY, Fizazi K
• Widespread and Functional RNA Circularization in Localized Prostate Cancer.
  Cell 2019 Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, Lapuk A, Chua MLK, Heisler LE, Foucal A, Fox NS, …
• Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
  European urology 2019 Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT
• Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models.
  JAMA network open 2019 Beesley LJ, Morgan TM, Spratt DE, Singhal U, Feng FY, Furgal AC, Jackson WC, Daignault S, Taylor JMG
• International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.
  The Journal of urology 2019 Berlin A, Moraes FY, Sanmamed N, Glicksman R, Koven A, Espin-Garcia O, Leite ETT, Silva JLF, Gadia R, Nesbitt M, Catton CN, Kaffenberger S, Salami SS, Morgan TM, Hearn JWD, Jackson WC, Mehra R, Chung …
• Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores.
  European urology 2019 Mahal BA, Alshalalfa M, Spratt DE, Davicioni E, Zhao SG, Feng FY, Rebbeck TR, Nguyen PL, Huang FW
• ONECUT2 is a driver of neuroendocrine prostate cancer.
  Nature communications 2019 Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M,…
• Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer.
  European urology oncology 2019 Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M, Hope TA, Carroll PR, Feng FY
• What Is Oligometastatic Prostate Cancer?
  European urology focus 2019 Fraser M, Koontz B, Emmenegger U, De Meerleer G, Khoo V, Feng F, Corcoran NM, Hovens CM, Tran PT, Ost P, Boutros PC, GAP6 Consortium
• Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer.
  Urology 2018 Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach M, Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA
• Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, …
• Reply to A. Dalla Volta et al.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Aggarwal R, Huang J, Alumkal J, Feng FY, Zhang L, Stuart JM, Small EJ
• Search for Subsolar-Mass Ultracompact Binaries in Advanced LIGO's First Observing Run.
  Physical review letters 2018 Abbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, …
• Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer.
  The Lancet. Oncology 2018 Miyamoto DT, Mouw KW, Feng FY, Shipley WU, Efstathiou JA
• PARP-1 regulates DNA repair factor availability.
  EMBO molecular medicine 2018 Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R, Zhao SG, Evans J, Han S, Parsons T, Birbe R, McCue P, McNair C, Chand SN, Cendon-Florez Y, Gallagher P, McCann JJ, Poudel Neupane N, …
• Integrative epigenetic taxonomy of primary prostate cancer.
  Nature communications 2018 Stelloo S, Nevedomskaya E, Kim Y, Schuurman K, Valle-Encinas E, Lobo J, Krijgsman O, Peeper DS, Chang SL, Feng FY, Wessels LFA, Henrique R, Jerónimo C, Bergman AM, Zwart W
• Long non-coding RNAs in prostate cancer: Biological and clinical implications.
  Molecular and cellular endocrinology 2018 Das R, Feng FY, Selth LA
• Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
  European urology 2018 Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL
• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
  Cell 2018 Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, …
• [Advances in globular glial tauopathies].
  Zhonghua nei ke za zhi 2018 Feng F, Zhang X, Wang LN
• [Tauopathy: the gradually concerned neurodegenerative diseases].
  Zhonghua nei ke za zhi 2018 Wang LN, Zhu MW, Feng F
• [The efficacy of cognitive behavioral therapy in insomnic patients with or without comorbidities: a pilot study].
  Zhonghua nei ke za zhi 2018 Wu YT, Wang J, Chen YW, Guo W, Wu EL, Tang CR, Feng F, Feng YS
• Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.
  European urology oncology 2018 Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JWD, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, …
• MechRNA: prediction of lncRNA mechanisms from RNA-RNA and RNA-protein interactions.
  Bioinformatics (Oxford, England) 2018 Gawronski AR, Uhl M, Zhang Y, Lin YY, Niknafs YS, Ramnarine VR, Malik R, Feng F, Chinnaiyan AM, Collins CC, Sahinalp SC, Backofen R
• [Value of MRI in the pre-operative diagnosis and classification of oblique vaginal septum syndrome].
  Zhonghua fu chan ke za zhi 2018 Wang Y, Lin Q, Sun ZJ, Jiang B, Hou B, Lu JJ, Zhu L, Feng F, Jin ZY, Lang JH
• DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
  Journal of the National Comprehensive Cancer Network : JNCCN 2018 Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ
• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
  Cell 2018 Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, …
• Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19.
  Cell 2018 Hua JT, Ahmed M, Guo H, Zhang Y, Chen S, Soares F, Lu J, Zhou S, Wang M, Li H, Larson NB, McDonnell SK, Patel PS, Liang Y, Yao CQ, van der Kwast T, Lupien M, Feng FY, Zoubeidi A, Tsao MS, Thibodeau SN…
• Re: Amar U. Kishan, Rahul D. Tendulkar, Phuoc T. Tran, et al. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Adenocarcinoma. Eur Urol Oncol. In press: Primum Non Nocere: Adding Hormone Therapy to Early Salvage Radiotherapy Makes the Physician Feel Better, But Does It Help the Patient?
  European urology oncology 2018 Spratt DE, Feng FY
• Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D,…
• [Resting-state functional MRI studies of amyotrophic lateral sclerosis patients with various levels of cognitive impairment].
  Zhonghua yi xue za zhi 2018 Shen DC, Hou B, Cui B, Li XL, Peng P, Tai HF, Zhang K, Liu SW, Fu HH, Liu MS, Feng F, Cui LY
• Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
  Cell 2018 Wu YM, Cieslik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A, PCF/SU2C International …
• EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
  Cancer research 2018 Gollavilli PN, Pawar A, Wilder-Romans K, Natesan R, Engelke CG, Dommeti VL, Krishnamurthy PM, Nallasivam A, Apel IJ, Xu T, Qin ZS, Feng FY, Asangani IA
• Effect of matrine on reducing damage to bovine mammary epithelial cells induced by Staphylococcus aureus alpha-hemolysin.
  Polish journal of veterinary sciences 2018 Feng F, Wa MM, Luo HX, Guan CP, Zhou XZ
• Genomic biomarkers in prostate cancer.
  Translational andrology and urology 2018 Kornberg Z, Cooperberg MR, Spratt DE, Feng FY
• Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.
  Nature genetics 2018 Zhang Y, Pitchiaya S, Cieslik M, Niknafs YS, Tien JC, Hosono Y, Iyer MK, Yazdani S, Subramaniam S, Shukla SK, Jiang X, Wang L, Liu TY, Uhl M, Gawronski AR, Qiao Y, Xiao L, Dhanasekaran SM, Juckette KM…
• The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.
  European urology 2018 Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, Simko JP, Cowan JE, Lehrer J, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes M, Plessis MD, Buerki C, Tenggara I, Davicioni E…
• Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, …
• Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways.
  Annals of translational medicine 2018 Kornberg Z, Chou J, Feng FY, Ryan CJ
• Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.
  Annals of oncology : official journal of the European Society for Medical Oncology 2018 Liu C, Wang L, Zhuang J, Liu L, Zhou C, Feng F, Sun C
• Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Okunieff P, Casey-Sawicki K, Lockney NA, Hoppe BS, Enderling H, Pinnix C, Welsh J, Krishnan S, Yothers G, Brown M, Knox S, Bristow R, Spellman P, Mitin T, Nabavizadeh N, Jaboin J, Manning HC, Feng F, …
• Live to SABR Another Day?
  International journal of radiation oncology, biology, physics 2018 Tran PT, Feng F, Ost P
• Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation.
  Cell reports 2018 Vasudevan HN, Braunstein SE, Phillips JJ, Pekmezci M, Tomlin BA, Wu A, Reis GF, Magill ST, Zhang J, Feng FY, Nicholaides T, Chang SM, Sneed PK, McDermott MW, Berger MS, Perry A, Raleigh DR
• Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, Feng FY, Speers C, Overmoyer B, Sabel M, Schott AF, Pierce L, Translational Breast Cancer Research Consortium
• Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
  European urology 2018 Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL
• Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
  Molecular cancer research : MCR 2018 Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM
• Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer.
  Annals of oncology : official journal of the European Society for Medical Oncology 2018 Yang DD, Krasnova A, Nead KT, Choueiri TK, Hu JC, Hoffman KE, Yu JB, Spratt DE, Feng FY, Trinh QD, Nguyen PL
• Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer.
  International journal of radiation oncology, biology, physics 2018 Dess RT, Devasia TP, Aghdam N, Jackson WC, Soni PD, Smith CP, Mitchell AL, Suy S, Hamstra DA, Jolly S, Nguyen PL, Feng FY, Schipper MJ, Skolarus TA, Miller DC, Wittmann DA, Collins SP, Spratt DE
• Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival.
  European urology 2018 Jackson WC, Suresh K, Tumati V, Allen SG, Dess RT, Salami SS, George A, Kaffenberger SD, Miller DC, Hearn JWD, Jolly S, Mehra R, Hollenbeck BK, Palapattu GS, Schipper M, Feng FY, Morgan TM, Desai NB, …
• Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in Prostate Cancer Involving Radiotherapy.
  American journal of clinical oncology 2018 Moraes FY, Leite ETT, Hamstra DA, Feng FY, Arruda FF, Gadia R, Abreu CECV, Marta GN, Hanna SA, Silva JLFD, Carvalho HA, Spratt DE
• Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, …
• Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA.
  Cell 2017 Hosono Y, Niknafs YS, Prensner JR, Iyer MK, Dhanasekaran SM, Mehra R, Pitchiaya S, Tien J, Escara-Wilke J, Poliakov A, Chu SC, Saleh S, Sankar K, Su F, Guo S, Qiao Y, Freier SM, Bui HH, Cao X, Malik R…
• Travel distance and stereotactic body radiotherapy for localized prostate cancer.
  Cancer 2017 Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF, Nguyen PL
• Differential impact of RB status on E2F1 reprogramming in human cancer.
  The Journal of clinical investigation 2017 McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, De Laere B, Dirix L, Visakorpi T, Li F, Feng FY, de Bono J, Demichelis F, Rubin MA, Brown M, Knudsen KE
• Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.
  JAMA oncology 2017 Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, …
• Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
  Journal of the National Cancer Institute 2017 Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME
• Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, …
• Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol 2018;73:156-65: Salvage Radiotherapy and Hormone Therapy: Change Is Coming, Just Not Quite Yet.
  European urology 2017 Spratt DE, Dess RT, Feng FY
• Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.
  Oncotarget 2017 Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, …
• LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.
  Cancer research 2017 Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, Karnes RJ, Chadwick D, van der Kwast T, Boutros PC, Arrowsmith CH, …
• TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, …
• Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection.
  Advanced healthcare materials 2017 Shen MY, Chen JF, Luo CH, Lee S, Li CH, Yang YL, Tsai YH, Ho BC, Bao LR, Lee TJ, Jan YJ, Zhu YZ, Cheng S, Feng FY, Chen P, Hou S, Agopian V, Hsiao YS, Tseng HR, Posadas EM, Yu HH
• [Clinical research of minimally invasive spine surgery with Vesselplasty].
  Zhonghua yi xue za zhi 2017 Tang H, Jia P, Chen H, Bao L, Feng F, Li JJ
• Co-expression of lipase isozymes for enhanced expression in Pichia pastoris.
  Letters in applied microbiology 2017 Cai H, Zhang T, Zhao M, Mao J, Cai C, Feng F
• Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer.
  NPJ breast cancer 2017 Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng FY
• Erectile function after stereotactic body radiotherapy for localized prostate cancer.
  BJU international 2017 Dess RT, Hartman HE, Aghdam N, Jackson WC, Soni PD, Abugharib AE, Suy S, Desai NB, Zumsteg ZS, Mehra R, Morgan TM, Feng FY, Hamstra DA, Schipper MJ, Collins SP, Spratt DE
• A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.
  Practical radiation oncology 2017 Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA
• Modulation of periodontitis progression using pH-responsive nanosphere encapsulating metronidazole or N-phenacylthialzolium bromide.
  Journal of periodontal research 2017 Lin JH, Feng F, Yu MC, Wang CH, Chang PC
• Risk of low-energy fracture in type 2 diabetes patients: a meta-analysis of observational studies.
  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2017 Jia P, Bao L, Chen H, Yuan J, Liu W, Feng F, Li J, Tang H
• Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities.
  Immunotherapy 2017 Green M, Feng FY, Mehra R, Spratt DE
• High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir ≤0.2 to Select Men for Short-term Hormonal Therapy.
  American journal of clinical oncology 2017 Son CH, Hamstra DA, Feng FY, Liauw SL
• Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation.
  Cancer research 2017 Yin Y, Li R, Xu K, Ding S, Li J, Baek G, Ramanand SG, Ding S, Liu Z, Gao Y, Kanchwala MS, Li X, Hutchinson R, Liu X, Woldu SL, Xing C, Desai NB, Feng FY, Burma S, de Bono JS, Dehm SM, Mani RS, Chen …
• A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.
  European urology 2017 Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY
• Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer.
  Current urology reports 2017 Dess RT, Morgan TM, Nguyen PL, Mehra R, Sandler HM, Feng FY, Spratt DE
• Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
  European urology 2017 Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP…
• Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
  European urology focus 2017 Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL
• Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications.
  Oncology (Williston Park, N.Y.) 2017 Aggarwal RR, Feng FY, Small EJ
• Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.
  Proceedings of the National Academy of Sciences of the United States of America 2017 Fei T, Chen Y, Xiao T, Li W, Cato L, Zhang P, Cotter MB, Bowden M, Lis RT, Zhao SG, Wu Q, Feng FY, Loda M, He HH, Liu XS, Brown M
• Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference.
  International journal of radiation oncology, biology, physics 2017 Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY
• Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.
  Cell reports 2017 Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho …
• Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
  European urology 2017 Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, Spratt DE, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, Kolisnik T, Margrave J, Yousefi K, …
• Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy.
  Urologic oncology 2017 Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL
• Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017 Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR
• External beam radiation therapy with or without low-dose-rate brachytherapy: Analysis of favorable and unfavorable intermediate-risk prostate cancer patients.
  Brachytherapy 2017 Abugharib AE, Dess RT, Soni PD, Narayana V, Evans C, Gaber MS, Feng FY, McLaughlin PW, Spratt DE
• Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
  Annals of oncology : official journal of the European Society for Medical Oncology 2017 Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL
• Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
  Cancer discovery 2017 Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, …
• Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer.
  Prostate international 2017 Sinha S, Muralidhar V, Feng FY, Nguyen PL
• Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LLC, du Plessis M, Choeurng V, Haddad Z, Buerki C, Davicioni E, …
• Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.
  BJU international 2017 Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck …
• National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.
  International journal of radiation oncology, biology, physics 2017 Yang DD, Muralidhar V, Mahal BA, Labe SA, Nezolosky MD, Vastola ME, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Spratt DE, Hoffman KE, Feng FY, Nguyen PL
• Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
  The New England journal of medicine 2017 Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal …
• Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer.
  Prostate cancer and prostatic diseases 2017 Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY
• Pan-Cancer Analysis of Genomic Sequencing Among the Elderly.
  International journal of radiation oncology, biology, physics 2017 Wahl DR, Nguyen PL, Santiago M, Yousefi K, Davicioni E, Shumway DA, Speers C, Mehra R, Feng FY, Osborne JR, Spratt DE
• MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2.
  Cancer research 2016 Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson AR, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, Ross AE, Den RB, Klein EA, Chi…
• Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
  Cancer 2016 Dess RT, Jackson WC, Suy S, Soni PD, Lee JY, Abugharib AE, Zumsteg ZS, Feng FY, Hamstra DA, Collins SP, Spratt DE
• Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
  Molecular cancer 2016 Tan M, Xu J, Siddiqui J, Feng F, Sun Y
• Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis.
  Cancer research 2016 Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, Zhao L, Kachman M, Wernisch S, Burant CF, Morgan MA, Feng FY, Speers C, Lyssiotis CA, Lawrence TS
• RB Loss Promotes Prostate Cancer Metastasis.
  Cancer research 2016 Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment SJ, Cotzia P, Dean JL, Snook A, McNair C, Price M, Hernandez JR, Zhao SG, Birbe R, McCarthy JB, Turley EA, …
• Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis.
  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2016 Zhao R, Wang H, Wang X, Feng F
• Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.
  Prostate cancer and prostatic diseases 2016 Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, Hurley P, Bishop JL, Tosoian J, Ghabili K, Alshalalfa M, Glavaris S, Simons BW, Tran P, Davicioni E, Karnes RJ, Boudadi K, Antonarakis ES, …
• Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, …
• Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.
  The Lancet. Oncology 2016 Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, …
• Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
  Journal of the National Cancer Institute 2016 Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM
• Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report.
  Urology case reports 2016 Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, Thangavel C, Seiler R, Feng FY, Schaeffer …
• Cell cycle-coupled expansion of AR activity promotes cancer progression.
  Oncogene 2016 McNair C, Urbanucci A, Comstock CE, Augello MA, Goodwin JF, Launchbury R, Zhao SG, Schiewer MJ, Ertel A, Karnes J, Davicioni E, Wang L, Wang Q, Mills IG, Feng FY, Li W, Carroll JS, Knudsen KE
• The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.
  Nature communications 2016 Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, Prensner JR, Poliakov A, Singhal U, Xiao L, Kregel S, Siebenaler RF, Zhao SG, Uhl M, Gawronski A, …
• Comparison of clinicopathological features and prognosis of gastric cancer located in the lesser and greater curve.
  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2016 Feng F, Tian Y, Guo M, Liu S, Xu G, Liu Z, Zheng G, Lian X, Fan D, Zhang H
• Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy.
  Seminars in radiation oncology 2016 Hall WA, Lawton CA, Jani AB, Pollack A, Feng FY
• Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival.
  The Journal of urology 2016 Abugharib A, Jackson WC, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Zumsteg ZS, Mehra R, Feng FY, Morgan TM, Desai N, Spratt DE
• Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study.
  International journal of radiation oncology, biology, physics 2016 Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, …
• Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer.
  Nature genetics 2016 Guo H, Ahmed M, Zhang F, Yao CQ, Li S, Liang Y, Hua J, Soares F, Sun Y, Langstein J, Li Y, Poon C, Bailey SD, Desai K, Fei T, Li Q, Sendorek DH, Fraser M, Prensner JR, Pugh TJ, Pomerantz M, Bristow RG…
• Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer.
  Brachytherapy 2016 Chen YW, Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Choueiri TK, Hoffman KE, Martin NE, Orio PF, Sweeney CJ, Feng FY, Trinh QD, Nguyen PL
• Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding.
  International journal of radiation oncology, biology, physics 2016 Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, …
• Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer.
  Neoplasia (New York, N.Y.) 2016 Shukla S, Zhang X, Niknafs YS, Xiao L, Mehra R, Cieslik M, Ross A, Schaeffer E, Malik B, Guo S, Freier SM, Bui HH, Siddiqui J, Jing X, Cao X, Dhanasekaran SM, Feng FY, Chinnaiyan AM, Malik R
• Racial/Ethnic Disparities in Genomic Sequencing.
  JAMA oncology 2016 Spratt DE, Chan T, Waldron L, Speers C, Feng FY, Ogunwobi OO, Osborne JR
• The bright side of dark matter: lncRNAs in cancer.
  The Journal of clinical investigation 2016 Evans JR, Feng FY, Chinnaiyan AM
• National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?
  Cancer 2016 Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL
• Reply to Yu-Wen Hu's Letter to the Editor re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7.
  European urology 2016 Jackson WC, Schipper MJ, Feng FY
• Long noncoding RNAs in prostate cancer: overview and clinical implications.
  Asian journal of andrology 2016 Malik B, Feng FY
• [Association between cured meat consumption and risk of colorectal cancer in people with different dietary habits and lifestyles].
  Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 2016 Li YL, Feng F, Yan J, Chen LL, Li XL, Liu WH, Yang YF
• Translational and clinical implications of the genetic landscape of prostate cancer.
  Nature reviews. Clinical oncology 2016 Spratt DE, Zumsteg ZS, Feng FY, Tomlins SA
• Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Speers C, Zhao SG, Kothari V, Santola A, Liu M, Wilder-Romans K, Evans J, Batra N, Bartelink H, Hayes DF, Lawrence TS, Brown PH, Pierce LJ, Feng FY
• Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up.
  Prostate cancer and prostatic diseases 2016 Spratt DE, Jackson WC, Abugharib A, Tomlins SA, Dess RT, Soni PD, Lee JY, Zhao SG, Cole AI, Zumsteg ZS, Sandler H, Hamstra D, Hearn JW, Palapattu G, Mehra R, Morgan TM, Feng FY
• Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
  Annals of oncology : official journal of the European Society for Medical Oncology 2016 Udager AM, Liu TY, Skala SL, Magers MJ, McDaniel AS, Spratt DE, Feng FY, Siddiqui J, Cao X, Fields KL, Morgan TM, Palapattu GS, Weizer AZ, Chinnaiyan AM, Alva A, Montgomery JS, Tomlins SA, Jiang H, …
• Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy.
  International journal of radiation oncology, biology, physics 2016 Sapir E, Tao Y, Feng F, Samuels S, El Naqa I, Murdoch-Kinch CA, Feng M, Schipper M, Eisbruch A
• Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk.
  Prostate cancer and prostatic diseases 2016 Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Klein EA, Dicker AP, Freedland SJ, …
• Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy.
  Urologic oncology 2016 Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, Palapattu GS, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng FY, Morgan TM
• Independent surgical validation of the new prostate cancer grade-grouping system.
  BJU international 2016 Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM
• Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes.
  European urology focus 2016 Spratt DE, Chen YW, Mahal BA, Osborne JR, Zhao SG, Morgan TM, Palapattu G, Feng FY, Nguyen PL
• Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy.
  American journal of clinical oncology 2016 Vainshtein JM, Schipper M, Vance S, Feng FY, Olson KB, Hamstra DA
• MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
  Neoplasia (New York, N.Y.) 2016 Feng FY, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S, Hamstra DA
• Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
  JAMA oncology 2016 Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, …
• Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer.
  Journal of the National Comprehensive Cancer Network : JNCCN 2016 Muralidhar V, Catalano PJ, Reznor G, Mahal BA, Choueiri TK, Sweeney CJ, Martin NE, Beard CJ, Chen YW, Nezolosky MD, Hoffman KE, Feng FY, Trinh QD, Nguyen PL
• National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study.
  Cancer 2016 Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio PF, Nguyen PL
• Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.
  Prostate cancer and prostatic diseases 2016 Morgan TM, Hawken SR, Ghani KR, Miller DC, Feng FY, Linsell SM, Salisz JA, Gao Y, Montie JE, Cher ML
• Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer.
  Journal of contemporary brachytherapy 2016 Muralidhar V, Xiang M, Orio PF, Martin NE, Beard CJ, Feng FY, Hoffman KE, Nguyen PL
• Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.
  The Journal of urology 2016 Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R
• microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients.
  Molecular biology reports 2016 Bakkar A, Alshalalfa M, Petersen LF, Abou-Ouf H, Al-Mami A, Hegazy SA, Feng F, Alhajj R, Bijian K, Alaoui-Jamali MA, Bismar TA
• Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.
  European urology 2016 Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah NL, Abdollah F, Feng FY, Davicioni E, Dicker AP, Karnes RJ, Den RB
• BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.
  Molecular cancer research : MCR 2016 Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM
• Driven to metastasize: Kinases as potential therapeutic targets in prostate cancer.
  Proceedings of the National Academy of Sciences of the United States of America 2016 Feng FY, Kothari V
• Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.
  Neoplasia (New York, N.Y.) 2016 Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM
• Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.
  European urology 2015 Mehra R, Udager AM, Ahearn TU, Cao X, Feng FY, Loda M, Petimar JS, Kantoff P, Mucci LA, Chinnaiyan AM
• Sevoflurane induces neurotoxicity in young mice through FAS/FASL signaling.
  Genetics and molecular research : GMR 2015 Song Q, Ma YL, Song JQ, Chen Q, Xia GS, Ma JY, Feng F, Fei XJ, Wang QM
• Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy.
  Cancer research 2015 McDaniel AS, Hovelson DH, Cani AK, Liu CJ, Zhai Y, Zhang Y, Weizer AZ, Mehra R, Feng FY, Alva AS, Morgan TM, Montgomery JS, Siddiqui J, Sadis S, Bandla S, Williams PD, Cho KR, Rhodes DR, Tomlins SA
• Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer.
  International journal of radiation oncology, biology, physics 2015 Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF, Nguyen PL
• A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy.
  Advances in radiation oncology 2015 Jackson WC, Feng FY, Daignault S, Hussain M, Smith D, Cooney K, Pienta K, Jolly S, Hollenbeck B, Olson KB, Sandler HM, Ray ME, Hamstra DA
• The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, Nguyen PL, Davicioni E, Feng FY
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
  The New England journal of medicine 2015 Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, …
• Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial.
  Head & neck 2015 Zhao SG, Alexander NB, Djuric Z, Zhou J, Tao Y, Schipper M, Feng FY, Eisbruch A, Worden FP, Strath SJ, Jolly S
• Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology.
  Medical oncology (Northwood, London, England) 2015 Magers MJ, Zhan T, Udager AM, Wei JT, Tomlins SA, Wu AJ, Kunju LP, Lew M, Feng FY, Hamstra DA, Siddiqui J, Chinnaiyan AM, Montgomery JS, Weizer AZ, Morgan TM, Hollenbeck BK, Miller DC, Palapattu GS, …
• Time to Nadir PSA: Of Popes and PSA--The Immortality Bias.
  American journal of clinical oncology 2015 Johnson SB, Jackson WC, Murgic J, Feng FY, Hamstra DA
• Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer.
  BJU international 2015 Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Feng FY, Martin NE, Efstathiou JA, Choueiri TK, Pomerantz MM, Sweeney CJ, Trinh QD, Vander Heiden MG, Nguyen PL
• Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?
  BJU international 2015 Mahal BA, Muralidhar V, Chen YW, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Trinh QD, Nguyen PL
• Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.
  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2015 Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng FY, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, …
• Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy.
  American journal of clinical oncology 2015 Jackson WC, Johnson SB, Feng FY, Hamstra DA
• Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.
  International journal of radiation oncology, biology, physics 2015 Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL
• Integrative Clinical Genomics of Advanced Prostate Cancer.
  Cell 2015 Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng…
• DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.
  Cancer cell 2015 Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA…
• Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists.
  Urology 2015 Nguyen PL, Shin H, Yousefi K, Thompson DJ, Hornberger J, Hyatt AS, Badani KK, Morgan TM, Feng FY
• Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.
  Molecular cell 2015 Feng FY, de Bono JS, Rubin MA, Knudsen KE
• Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
  Neoplasia (New York, N.Y.) 2015 Zaslavsky AB, Gloeckner-Kalousek A, Adams M, Putluri N, Venghatakrishnan H, Li H, Morgan TM, Feng FY, Tewari M, Sreekumar A, Palapattu GS
• Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
  European urology 2015 Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY
• Integrative clinical genomics of advanced prostate cancer.
  Cell 2015 Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng…
• High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.
  Prostate cancer and prostatic diseases 2015 Zhao SG, Jackson WC, Kothari V, Schipper MJ, Erho N, Evans JR, Speers C, Hamstra DA, Niknafs YS, Nguyen PL, Schaeffer EM, Ross AE, Den RB, Klein EA, Jenkins RB, Davicioni E, Feng FY
• Development and validation of a novel platform-independent metastasis signature in human breast cancer.
  PloS one 2015 Zhao SG, Shilkrut M, Speers C, Liu M, Wilder-Romans K, Lawrence TS, Pierce LJ, Feng FY
• Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
  European urology 2015 Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY
• Consequence of the tumor-associated conversion to cyclin D1b.
  EMBO molecular medicine 2015 Augello MA, Berman-Booty LD, Carr R, Yoshida A, Dean JL, Schiewer MJ, Feng FY, Tomlins SA, Gao E, Koch WJ, Benovic JL, Diehl JA, Knudsen KE
• Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5.
  Brachytherapy 2015 Liss AL, Abu-Isa EI, Jawad MS, Feng FY, Vance SM, Winfield RJ, Narayana V, Sandler HM, McLaughlin PW, Hamstra DA
• Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Speers C, Zhao S, Liu M, Bartelink H, Pierce LJ, Feng FY
• Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series.
  Asian journal of urology 2015 Koloff ZB, Hamstra DA, Wei JT, Montgomery JS, Tomlins SA, Wu AJ, Morgan TM, Siddiqui J, Paich K, Chinnaiyan AM, Feng FY, Weizer AZ, Kunju LP, Hollenbeck BK, Miller DC, Palapattu GS, Mehra R
• Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
  Neoplasia (New York, N.Y.) 2015 Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, Gottimukkala R, Liu G, Manivannan M, Schageman J, Ballesteros-Villagrana E, Grasso CS, Quist …
• Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer.
  International journal of radiation oncology, biology, physics 2015 Vainshtein JM, Moon DH, Feng FY, Chepeha DB, Eisbruch A, Stenmark MH
• Targeting the MLL complex in castration-resistant prostate cancer.
  Nature medicine 2015 Malik R, Khan AP, Asangani IA, Cieslik M, Prensner JR, Wang X, Iyer MK, Jiang X, Borkin D, Escara-Wilke J, Stender R, Wu YM, Niknafs YS, Jing X, Qiao Y, Palanisamy N, Kunju LP, Krishnamurthy PM, Yocum…
• Integrative molecular profiling of routine clinical prostate cancer specimens.
  Annals of oncology : official journal of the European Society for Medical Oncology 2015 Grasso CS, Cani AK, Hovelson DH, Quist MJ, Douville NJ, Yadati V, Amin AM, Nelson PS, Betz BL, Liu CJ, Knudsen KE, Cooney KA, Feng FY, McDaniel AS, Tomlins SA
• Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ
• The landscape of long noncoding RNAs in the human transcriptome.
  Nature genetics 2015 Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu YM, Robinson DR, Beer DG, Feng FY, Iyer HK, Chinnaiyan AM
• Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma.
  Virchows Archiv : an international journal of pathology 2014 Warrick JI, Hovelson DH, Amin A, Liu CJ, Cani AK, McDaniel AS, Yadati V, Quist MJ, Weizer AZ, Brenner JC, Feng FY, Mehra R, Grasso CS, Tomlins SA
• A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer.
  Neoplasia (New York, N.Y.) 2014 Mehra R, Shi Y, Udager AM, Prensner JR, Sahu A, Iyer MK, Siddiqui J, Cao X, Wei J, Jiang H, Feng FY, Chinnaiyan AM
• Editorial comment.
  Urology 2014 Morgan TM, Feng FY
• Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy.
  Radiation oncology (London, England) 2014 Foster CC, Jackson WC, Foster BC, Johnson SB, Feng FY, Hamstra DA
• The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc.
  Neoplasia (New York, N.Y.) 2014 Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, Evans JR, Knudsen KE, Paulsen MT, Ljungman M, Lawrence TS, Chinnaiyan AM, Feng FY
• RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
  The Lancet. Oncology 2014 Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM,…
• A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer.
  Translational oncology 2014 Cuneo KC, Chenevert TL, Ben-Josef E, Feng MU, Greenson JK, Hussain HK, Simeone DM, Schipper MJ, Anderson MA, Zalupski MM, Al-Hawary M, Galban CJ, Rehemtulla A, Feng FY, Lawrence TS, Ross BD
• A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY
• Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer.
  Breast cancer research and treatment 2014 Feng FY, Speers C, Liu M, Jackson WC, Moon D, Rinkinen J, Wilder-Romans K, Jagsi R, Pierce LJ
• The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer.
  Molecular cancer research : MCR 2014 Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, Subramaniyan S, Carley A, Niknafs YS, Sahu A, Han S, Ma T, Liu M, Asangani IA, Jing X, Cao X, Dhanasekaran SM, Robinson DR, Feng FY, Chinnaiyan AM
• MRI to delineate the gross tumor volume of nasopharyngeal cancers: which sequences and planes should be used?
  Radiology and oncology 2014 Popovtzer A, Ibrahim M, Tatro D, Feng FY, Ten Haken RK, Eisbruch A
• Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.
  International journal of radiation oncology, biology, physics 2014 Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP
• Molecular pathways: targeting ETS gene fusions in cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Feng FY, Brenner JC, Hussain M, Chinnaiyan AM
• Understanding the relationship between tumor size, gland size, and disease aggressiveness in men with prostate cancer.
  Urology 2014 Kozminski MA, Palapattu GS, Mehra R, Montgomery JS, Weizer AZ, Skolarus TA, Hollenbeck BK, Miller DC, He C, Tomlins S, Montie JE, Feng FY, Wood DP, Kunju LP, Morgan TM
• A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer1,2.
  Translational oncology 2014 Zhao S, Chang SL, Linderman JJ, Feng FY, Luker GD
• Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study.
  International journal of radiation oncology, biology, physics 2014 Vainshtein JM, Griffith KA, Feng FY, Vineberg KA, Chepeha DB, Eisbruch A
• Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
  Nature 2014 Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM
• Long interspersed nucleotide acid element-1 ORF-1 protein promotes proliferation and invasion of human colorectal cancer LoVo cells through enhancing ETS-1 activity.
  Genetics and molecular research : GMR 2014 Li MY, Zhu M, Feng F, Cai FY, Fan KC, Jiang H, Wang ZQ, Linghu EQ
• The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer.
  Oncotarget 2014 Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, Poliakov A, Vergara IA, Alshalalfa M, Jenkins RB, Davicioni E, Feng FY, Chinnaiyan AM
• A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy.
  Practical radiation oncology 2014 Johnson S, Jackson W, Speers C, Feng F, Hamstra D
• Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis.
  International journal of radiation oncology, biology, physics 2014 Stenmark MH, McHugh JB, Schipper M, Walline HM, Komarck C, Feng FY, Worden FP, Wolf GT, Chepeha DB, Prince ME, Bradford CR, Mukherji SK, Eisbruch A, Carey TE
• Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer.
  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2014 Stenmark MH, Conlon AS, Johnson S, Daignault S, Litzenberg D, Marsh R, Ritter T, Vance S, Kazzi N, Feng FY, Sandler H, Sanda MG, Hamstra DA
• PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.
  Cancer research 2014 Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, …
• The first transcriptome and genetic linkage map for Asian arowana.
  Molecular ecology resources 2014 Shen XY, Kwan HY, Thevasagayam NM, Prakki SR, Kuznetsova IS, Ngoh SY, Lim Z, Feng F, Chang A, Orbán L
• The central role of EED in the orchestration of polycomb group complexes.
  Nature communications 2014 Cao Q, Wang X, Zhao M, Yang R, Malik R, Qiao Y, Poliakov A, Yocum AK, Li Y, Chen W, Cao X, Jiang X, Dahiya A, Harris C, Feng FY, Kalantry S, Qin ZS, Dhanasekaran SM, Chinnaiyan AM
• Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy.
  Neuro-oncology 2013 Farjam R, Tsien CI, Feng FY, Gomez-Hassan D, Hayman JA, Lawrence TS, Cao Y
• Characterization of changes in total body composition for patients with head and neck cancer undergoing chemoradiotherapy using dual-energy x-ray absorptiometry.
  Head & neck 2013 Jackson W, Alexander N, Schipper M, Fig L, Feng F, Jolly S
• A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.
  Prostate cancer and prostatic diseases 2013 Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM
• Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
  Neoplasia (New York, N.Y.) 2013 Han S, Brenner JC, Sabolch A, Jackson W, Speers C, Wilder-Romans K, Knudsen KE, Lawrence TS, Chinnaiyan AM, Feng FY
• The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.
  Nature genetics 2013 Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, Ma T, Chen W, Han S, Jing X, Cao X, Wang …
• Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
  Clinical oncology (Royal College of Radiologists (Great Britain)) 2013 Láng I, Bell R, Feng FY, Lopez RI, Jassem J, Semiglazov V, Al-Sakaff N, Heinzmann D, Chang J
• A hormone-DNA repair circuit governs the response to genotoxic insult.
  Cancer discovery 2013 Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, Ma T, Den RB, Dicker AP, Feng FY, Knudsen KE
• Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
  International journal of radiation oncology, biology, physics 2013 Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng FY
• Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy.
  Practical radiation oncology 2013 Jackson WC, Johnson SB, Foster B, Foster C, Li D, Song Y, Vainshtein J, Zhou J, Hamstra DA, Feng FY
• A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.
  Radiation oncology (London, England) 2013 Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY
• Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy.
  Cancer 2013 Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY
• Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx.
  Head & neck 2013 Dobrosotskaya IY, Bellile E, Spector ME, Kumar B, Feng F, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos T, Chepeha DB, Walline HM, McHugh JB, Cordell KG, Ward PD, Byrd S, Maxwell JH, Urba S, …
• Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors.
  Head & neck 2013 Hunter KU, Lee OE, Lyden TH, Haxer MJ, Feng FY, Schipper M, Worden F, Prince ME, McLean SA, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A
• Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
  International journal of radiation oncology, biology, physics 2013 Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA
• Identification of targetable FGFR gene fusions in diverse cancers.
  Cancer discovery 2013 Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury S, Hussain MH, Feng FY, …
• The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer.
  International journal of radiation oncology, biology, physics 2013 Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng F, Hamstra D
• Recurrent rearrangements in prostate cancer: causes and therapeutic potential.
  Current drug targets 2013 White NM, Feng FY, Maher CA
• Diffusion abnormality index: a new imaging biomarker for early assessment of tumor response to therapy.
  Practical radiation oncology 2013 Farjam R, Tsien CI, Feng FY, Hayman JA, Lawrence TS, Cao Y
• Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
  International journal of radiation oncology, biology, physics 2013 Feng FY, Blas K, Olson K, Stenmark M, Sandler H, Hamstra DA
• Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.
  The Journal of clinical investigation 2012 Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE
• Long PCR-RFLP of 16S-ITS-23S rRNA genes: a high-resolution molecular tool for bacterial genotyping.
  Journal of applied microbiology 2012 Zeng YH, Koblížek M, Li YX, Liu YP, Feng FY, Ji JD, Jian JC, Wu ZH
• Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer.
  International journal of radiation oncology, biology, physics 2012 Hamstra DA, Stenmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S, Albrecht-Unger L, Donaghy A, Phelps L, Blas K, Halverson S, Marsh R, Olson K, Feng FY
• Physiological imaging-defined, response-driven subvolumes of a tumor.
  International journal of radiation oncology, biology, physics 2012 Farjam R, Tsien CI, Feng FY, Gomez-Hassan D, Hayman JA, Lawrence TS, Cao Y
• Urethral cancer.
  Hematology/oncology clinics of North America 2012 Grivas PD, Davenport M, Montie JE, Kunju LP, Feng F, Weizer AZ
• 12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report.
  Urologic oncology 2012 Chang SS, Dinney CP, Donat SM, Dahm P, Gore JL, Lotan Y, Parekh DJ, Solit DB, O'Donnell PH, Feng FY, Hansel D, Milowsky MI
• Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes.
  International journal of radiation oncology, biology, physics 2012 Hunter KU, Schipper M, Feng FY, Lyden T, Haxer M, Murdoch-Kinch CA, Cornwall B, Lee CS, Chepeha DB, Eisbruch A
• General commentary to the "management of biochemical recurrence after primary localized therapy for prostate cancer" by darwish o. M. And raj g. V.
  Frontiers in oncology 2012 Shilkrut M, Feng F, Hamstra DA
• Dual roles of PARP-1 promote cancer growth and progression.
  Cancer discovery 2012 Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, Pascal JM, Centenera MM, Butler LM…
• The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
  Cancer 2012 Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA
• The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer.
  Radiation oncology (London, England) 2012 Murgic J, Stenmark MH, Halverson S, Blas K, Feng FY, Hamstra DA
• Risk factors for local recurrence and metastasis in soft tissue sarcomas of the extremity.
  American journal of clinical oncology 2012 Sabolch A, Feng M, Griffith K, Rzasa C, Gadzala L, Feng F, Biermann JS, Chugh R, Ray M, Ben-Josef E
• PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
  Cancer research 2012 Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA, Chinnaiyan AM
• Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms.
  International journal of radiation oncology, biology, physics 2012 Pak D, Vineberg K, Feng F, Ten Haken RK, Eisbruch A
• Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.
  International journal of radiation oncology, biology, physics 2011 Hunter KU, Feng FY, Griffith KA, Francis IR, Lawrence TS, Desai S, Murphy JD, Zalupski MM, Ben-Josef E
• Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy.
  International journal of radiation oncology, biology, physics 2011 Vance SM, Stenmark MH, Blas K, Halverson S, Hamstra DA, Feng FY
• Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
  International journal of radiation oncology, biology, physics 2011 Little M, Schipper M, Feng FY, Vineberg K, Cornwall C, Murdoch-Kinch CA, Eisbruch A
• Role of podoplanin expression in esophageal squamous cell carcinoma: a retrospective study.
  Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2011 Tong L, Yuan S, Feng F, Zhang H
• Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer.
  Cancer 2011 Kapadia NS, Olson K, Sandler HM, Feng FY, Hamstra DA
• Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy.
  International journal of radiation oncology, biology, physics 2011 Feng FY, Qian Y, Stenmark MH, Halverson S, Blas K, Vance S, Sandler HM, Hamstra DA
• The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: evaluation and optimization in patients at higher risk of relapse.
  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011 Halverson S, Schipper M, Blas K, Lee V, Sabolch A, Olson K, Sandler HM, Feng FY, Hamstra DA
• Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
  International journal of radiation oncology, biology, physics 2011 Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA
• Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates.
  International journal of radiation oncology, biology, physics 2011 Eisbruch A, Kim HM, Feng FY, Lyden TH, Haxer MJ, Feng M, Worden FP, Bradford CR, Prince ME, Moyer JS, Wolf GT, Chepeha DB, Ten Haken RK
• Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.
  Cancer cell 2011 Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA,…
• Mongoliitalea lutea gen. nov., sp. nov., an alkaliphilic, halotolerant bacterium isolated from a haloalkaline lake.
  International journal of systematic and evolutionary microbiology 2011 Yang CX, Liu YP, Bao QH, Feng FY, Liu HR, Zhang XJ, Zhao YL
• Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation.
  International journal of radiation oncology, biology, physics 2011 Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L, Olson KB, Sandler HM, Hamstra DA
• Therapeutic targeting of SPINK1-positive prostate cancer.
  Science translational medicine 2011 Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM
• The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.
  International journal of radiation oncology, biology, physics 2011 Qian Y, Feng FY, Halverson S, Blas K, Sandler HM, Hamstra DA
• Role of radiotherapy in the management of desmoid tumors.
  International journal of radiation oncology, biology, physics 2010 Gluck I, Griffith KA, Biermann JS, Feng FY, Lucas DR, Ben-Josef E
• HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans.
  Head & neck 2010 Maxwell JH, Kumar B, Feng FY, McHugh JB, Cordell KG, Eisbruch A, Worden FP, Wolf GT, Prince ME, Moyer JS, Teknos TN, Chepeha DB, Stoerker J, Walline H, Carey TE, Bradford CR
• Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A
• Radiation dose-volume effects in the larynx and pharynx.
  International journal of radiation oncology, biology, physics 2010 Rancati T, Schwarz M, Allen AM, Feng F, Popovtzer A, Mittal B, Eisbruch A
• Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos TN, Chepeha DB, McHugh JB, Urba SG, Stoerker J, Walline HM, Kurnit DM, Cordell KG, Davis SJ, Ward PD, …
• Application of a self-made swivel intravenous transfusion device in constructing allogenic small bowel transplantation rejection model in rats.
  Transplantation proceedings 2009 Yang J, Li M, Zhang H, Hong L, Feng F, Pan F, Wang Y, Wang W
• A standard panel of microsatellites for Asian seabass (Lates calcarifer).
  Animal genetics 2009 Zhu ZY, Wang CM, Lo LC, Lin G, Feng F, Tan J, Chou R, Lim HS, Orban L, Yue GH
• Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer.
  International journal of radiation oncology, biology, physics 2009 Gluck I, Feng FY, Lyden T, Haxer M, Worden F, Chepeha DB, Eisbruch A
• RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells.
  Oncogene 2009 Jian Y, Gao Z, Sun J, Shen Q, Feng F, Jing Y, Yang C
• Anatomical changes in the pharyngeal constrictors after chemo-irradiation of head and neck cancer and their dose-effect relationships: MRI-based study.
  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2009 Popovtzer A, Cao Y, Feng FY, Eisbruch A
• Living-related small bowel transplantation for three patients with short gut syndrome.
  Transplantation proceedings 2008 Li M, Ji G, Feng F, Song W, Ling R, Chen D, Liu X, Li J, Shi H, Wang W, Zhang H
• Isolation and characterization of 51 microsatellites from BAC clones in Asian seabass, Lates calcarifer.
  Animal genetics 2008 Zhu ZY, Wang CM, Feng F, Yue GH
• Radiation therapy improves survival in patients with pancreatic adenocarcinoma.
  Nature clinical practice. Oncology 2008 Feng FY, Ben-Josef E
• Single nucleotide polymorphisms refine QTL intervals for hip joint laxity in dogs.
  Animal genetics 2008 Zhu L, Zhang Z, Feng F, Schweitzer P, Phavaphutanon J, Vernier-Singer M, Corey E, Friedenberg S, Mateescu R, Williams A, Lust G, Acland G, Todhunter R
• Identification and verification of QTL associated with growth traits in two genetic backgrounds of Barramundi (Lates calcarifer).
  Animal genetics 2007 Wang CM, Lo LC, Feng F, Zhu ZY, Yue GH
• Sonography of wrist ganglion cysts: variable and noncystic appearances.
  Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 2007 Wang G, Jacobson JA, Feng FY, Girish G, Caoili EM, Brandon C
• Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation.
  International journal of radiation oncology, biology, physics 2007 Lopez CA, Feng FY, Herman JM, Nyati MK, Lawrence TS, Ljungman M
• Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures.
  International journal of radiation oncology, biology, physics 2007 Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP, Chepeha DB, Eisbruch A
• Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Feng FY, Lopez CA, Normolle DP, Varambally S, Li X, Chun PY, Davis MA, Lawrence TS, Nyati MK
• Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences.
  International journal of radiation oncology, biology, physics 2007 Eisbruch A, Levendag PC, Feng FY, Teguh D, Lyden T, Schmitz PI, Haxer M, Noever I, Chepeha DB, Heijmen BJ
• Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation.
  Cancer research 2006 Nyati MK, Feng FY, Maheshwari D, Varambally S, Zielske SP, Ahsan A, Chun PY, Arora VA, Davis MA, Jung M, Ljungman M, Canman CE, Chinnaiyan AM, Lawrence TS
• Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity.
  Oncogene 2006 Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X, Davis MA, Chinnaiyan AM, Lawrence TS, Nyati MK
• Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more?
  Current drug targets 2006 Carr JM, Davis AJ, Feng F, Burrell CJ, Li P
• Integration of EGFR inhibitors with radiochemotherapy.
  Nature reviews. Cancer 2006 Nyati MK, Morgan MA, Feng FY, Lawrence TS
• Isolation, characterization, and linkage analyses of 74 novel microsatellites in Barramundi (Lates calcarifer).
  Genome 2006 Zhu ZY, Wang CM, Lo LC, Feng F, Lin G, Yue GH
• Chloroquine treatment increases detection of 5-fluorouracil-induced apoptosis index in vivo.
  Molecular imaging 2006 Nyati MK, Feng FY, Kanade VD, Nayak R
• Characterization of two parvalbumin genes and their association with growth traits in Asian seabass (Lates calcarifer).
  Animal genetics 2006 Xu YX, Zhu ZY, Lo LC, Wang CM, Lin G, Feng F, Yue GH
• Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma.
  Cancer research 2006 Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, Nyati MK
• The complete mitochondrial genome sequence and characterization of single-nucleotide polymorphisms in the control region of the Asian seabass (Lates calcarifer).
  Marine biotechnology (New York, N.Y.) 2006 Lin G, Lo LC, Zhu ZY, Feng F, Chou R, Yue GH
• Smaller inner ear sensory epithelia in Neurog 1 null mice are related to earlier hair cell cycle exit.
  Developmental dynamics : an official publication of the American Association of Anatomists 2005 Matei V, Pauley S, Kaing S, Rowitch D, Beisel KW, Morris K, Feng F, Jones K, Lee J, Fritzsch B
• Chemosensitization of breast carcinoma cells with the use of bcl-2 antisense oligodeoxynucleotide.
  Breast (Edinburgh, Scotland) 2004 Yang JH, Feng F, Qian H, Cheng H
• Refinement in quantitative convergent beam electron diffraction (QCBED).
  Ultramicroscopy 2004 Feng F, Zhang AH, Zhu J
• Determination of semivolatile compounds in drinking water by tandem mass spectrometric detection.
  Bulletin of environmental contamination and toxicology 2003 Huang Z, Zhou W, Zhou C, Han S, Zhang A, Feng F, Liu C, Wang L
• FK506 rescues peripheral nerve allografts in acute rejection.
  Journal of neurotrauma 2001 Feng FY, Ogden MA, Myckatyn TM, Grand AG, Jensen JN, Hunter DA, Mackinnon SE
• [The relationship between cadmium-induced inhibition of splenic lymphocyte function and cell apoptosis].
  Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 2001 Feng F, Xue B, Zhang X
• [Clinical analysis of 10 cases of true histiocytic lymphoma].
  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2000 Zhou A, Feng F, Shi Y
• [Simultaneous determination of fluoroacetamide and tetramethylendisulfotetramin with gas chromatography-mass spectrography].
  Wei sheng yan jiu = Journal of hygiene research 2000 Ma Y, Feng F, Chen B
• Mammary tumor development in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency.
  Breast cancer research and treatment 2000 Feng F, Rittling SR
• [Treatment of advanced Hodgkin's disease: an analysis of 128 cases].
  Zhonghua zhong liu za zhi [Chinese journal of oncology] 2000 Zhou L, Wang Q, Feng F
• Safe injection of cultured schwann cells into peripheral nerve allografts.
  Microsurgery 2000 Ogden MA, Feng FY, Myckatyn TM, Jensen JN, Grand AG, Wood PW, Hunter DA, MacKinnon SE
• [Expression of multidrug resistance-associated protein in human non-small cell lung cancer].
  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 1999 Peng X, Feng F, Zhang W
• [Phase II clinical study of a new anticancer drug boanmycin].
  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 1999 Feng F, Zhou L
• [Adrenal metastasis in primary lung cancer].
  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 1999 Wang H, Feng F, Zhang X
• [Expression of multidrug resistance-associated protein (MRP) and lung resistance protein (LRP) in human rectal carcinomas and its clinical significance].
  Zhonghua zhong liu za zhi [Chinese journal of oncology] 1999 Peng X, Feng F, Zhang W
• [Mitomycin, vindesine and cisplatin combination therapy in the treatment of advanced non-small cell lung cancer: a report of 108 cases].
  Zhonghua zhong liu za zhi [Chinese journal of oncology] 1999 Zhang X, Sun Y, Feng F
• Association of long variants of the dopamine D4 receptor exon 3 repeat polymorphism with Parkinson's disease.
  Clinical genetics 1998 Ricketts MH, Hamer RM, Manowitz P, Feng F, Sage JI, Di Paola R, Menza MA
• [Molecular cloning and DNA sequencing of OspC gene of two strains Borrelia burgdorferi isolated in China].
  Zhonghua yi xue za zhi 1998 Tong Y, Yang X, Feng F
• Comparison of radiography, computed tomography and magnetic resonance imaging in the detection of sacroiliitis accompanying ankylosing spondylitis.
  Skeletal radiology 1998 Yu W, Feng F, Dion E, Yang H, Jiang M, Genant HK
• [Studies on some characteristics of a strain of mink infectious enteritis virus].
  Wei sheng wu xue bao = Acta microbiologica Sinica 1996 Feng F, Li T, Ma Z, Chen P, Zhao L
• [A phase II clinical trial of pepleomycin].
  Zhonghua zhong liu za zhi [Chinese journal of oncology] 1996 Feng F, Zhang H
• [An experimental animal model study of HCMV].
  Wei sheng wu xue bao = Acta microbiologica Sinica 1996 Li T, Zhao L, Feng F, Chen S, Xia P
• Artificial neural network to assist psychiatric diagnosis.
  The British journal of psychiatry : the journal of mental science 1996 Zou Y, Shen Y, Shu L, Wang Y, Feng F, Xu K, Ou Y, Song Y, Zhong Y, Wang M, Liu W
• [Phase I clinical study of a new anticancer drug boanmycin].
  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 1996 Feng F, Zhou L, Mang Z, Liu H, Sun Y
• [The clinical efficacy of CAC regimen in the treatment of advanced breast cancer].
  Zhonghua zhong liu za zhi [Chinese journal of oncology] 1995 Zhang P, Zhou J, Feng F
• A practical procedure for the cryopreservation of marrow cells intended for autotransplantation.
  Leukemia & lymphoma 1995 Luo KH, Shi YK, Sun Y, Wang QL, Wu GQ, Feng FY, Cui W, Liu HB
• [Clinical study of recombinant human granulocyte colony-stimulating factor (RHG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients].
  Zhonghua nei ke za zhi 1994 Shi YK, Feng FY, Sun Y
• [Clinical study of recombinant human granulocyte colony stimulating factor (rhG-CSF) on leukopenia induced by chemotherapy in cancer patients].
  Zhonghua zhong liu za zhi [Chinese journal of oncology] 1994 Shi YK, Zhou JC, Feng FY
• Heterogeneous expression of alpha 1-adrenoceptor subtypes among rat nephron segments.
  Molecular pharmacology 1993 Feng F, Abel PW, Scofield M, Liu F, Wolff DW, Jeffries WB
• [High-dose methotrexate with citrovorum factor rescue (HD-MTX-CFR) in the treatment of malignant solid tumors--clinical analysis of 62 patients].
  Zhonghua zhong liu za zhi [Chinese journal of oncology] 1988 Wang QL, Sun Y, Zhou JC, Song SZ, Feng FY, Lu L, Yie ZS
• [COMVp regimen in the treatment of small cell lung cancer--report of 106 patients].
  Zhonghua zhong liu za zhi [Chinese journal of oncology] 1987 Sun Y, Yin WB, Feng FY, Wang JW, Qiu Q, Wang QL, Bai L, Zhou JC, Song SZ
• [Evaluation of combined chemotherapy including high-dose cisplatin in the treatment of malignant tumors].
  Zhonghua zhong liu za zhi [Chinese journal of oncology] 1987 Zhou JC, Feng FY, Sun Y, Wang QL, Zeng WY, Liu YY